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ABSTRACT

Opioid analgesics such as morphine and its derivatives are the most frequently
prescribed narcotics for the treatment of severe and chronic pain. Among other side
effects caused by the administration of these opioid analgesics, physical dependence and
addiction are the most undesirable ones. Currently, pharmacological approaches to treat
opioid dependence include mainly methadone and LAAM (μ-agonists), buprenorphine
(μ-partial agonist) and clonidine (α2-adrenergic agonist). Considering the negative
aspects of the relapsing nature correlated to opioid dependence, it is important to search
for new ways to overcome this problem. The scope of this work is to study novel
compounds based on the alkaloids present in Mitragynina speciosa (Korth), a tree
indigenous to Southeast Asia. Consumption of leave extracts of this plant have been
linked to the attenuation of the withdrawal syndrome associate with opioid dependence.
Taking into consideration the structure of the major alkaloid, mitragynine, two classes of
compounds

were

designed

and

synthesized:

phenylpiperidines,

including

phenylaminopiperidines and phenylamidopiperidines, and tetrahydro-β-carbolines. They
were further submitted to in vitro evaluation on μ-, δ- and κ-opioid receptors for their
binding affinities. Out of six piperidines submitted to biological evaluation, four revealed
significant affinity with Ki values in the micromolar range on either μ- and δ-receptors or
κ-opioid receptors. On the other hand, out of five tetrahydro-β-carbolines tested, two
showed κ-receptors affinities in the nanomolar range. Although none of the compounds
displayed binding affinities as high as mitragynine, it is possible to say that distinct
moieties attached to the piperidines had different selectivities among μ-, δ- and κ-opioid
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receptors. Tetrahydro-β-carbolines, which mimics the four-ringed structure of
mitragynine, showed only relevant affinity towards κ-receptors. The important factor for
the higher affinity of tetrahydro-β-carbolines, when compared to piperidines, is that their
less flexible structure is responsible for their greater affinity. More specifically, the
methyl acetyl moiety at the C15 position had higher affinity than the methyl
methoxyacrylate on κ-receptors. Unfortunately, this work did not focus on stereoselective
syntheses or chiral separations, which in the case of the chiral tetrahydro-β-carbolines
could have given valuable insights about the spatial requirements for affinity among the
three main opioid receptors.
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1. Pain
The perception of pain is an intrinsic part of life that is only perceived during
consciousness. Although uncomfortable to the individual, it is essential to protect the
body from harm. Hereditary insensitivity to pain, a rare syndrome, can lead to multiple
injuries such as biting ones tongue, burning or bone fractures without the person realizing
them. It is evident that not only human beings are capable of perceiving pain, but other
vertebrates can also experience it. Theories seeking explanations of the origin of pain
have followed mankind. It is not difficult to explain the pain caused by an accidental
injury; however pain sensation caused by an internal disease was not easy to understand.
Ancient cultures such as in Egypt usually tried to explain the causes of pain that was not
derived from an injury through the acts of gods and spirits of death1. Several medical
treatises written in Greek between 430 and 380 BC known as the Hippocratic Collection
gave attention to the causes of pain. There was some disagreement about the distinction
of humors, but the School of Cos considered that pain was caused by an imbalance of
four humors: phlegm, blood, yellow and black bile2. In the 17th and 18th centuries based
on the discoveries of natural sciences, medicine and physics, physicians began to treat the
parts of the human body as parts in a machine. One of the earliest concepts of modern
physiology proposed by René Descartes (1596 - 1650) depicted a touch that produces a
painful stimulus traveling from the peripheral endings all the way to the brain, where it
brings about an image of the stimulus in the soul1.
The development of modern physiology led not only to a better understanding of
the mechanisms that cause pain, but also to pathological states, such as increased
sensation of pain (hyperalgesia). Melzack and Wall proposed in the 1960's a gate control
1

theory of pain3. The cells in the substantia gelatinosa (a functional unit that extends the
length of the spinal cord) connect with one another by small and long fibers, but do not
project to other parts of the brain. Even in the absence of stimulus, the spinal cord is
bombarded by incoming nerve impulses carried predominantly by small fibers. As the
stimulus increase, more fibers are recruited to fire at a higher frequency, which produces
a change in the ratio between long and small fibers. The inhibitory effect of the substantia
gelatinosa is increased by the activity of long fibers and decreased by small fibers. A
gentle pressure in the skin leads not only to the firing of T cells (cells that connect to
other parts of the brain), but also close the presynaptic gate. If the stimulus is increased,
the gate opens further and the output of the T cells rises. The perception of pain is thus
marked by the actions of the T cells that interacts with the gate control system3. Although
the gate control theory of pain is probably wrong in various details, the authors believed
that their most important contribution was the emphasis on central nervous system (CNS)
mechanisms instead of explaining pain exclusively in terms of peripheral factors1.
From the periphery, painful stimuli trigger neurons to send signals to the dorsal
horn ganglia in the spinal cord, forming along with the brainstem and thalamus, the
spinothalamic tract. There are basically two types of connections: a direct spinothalamic
system, which carries sensory signals right to the thalamus, and a more diffuse system
called spinoreticulothalamic pathway that terminates in the brainstem and reticular
nuclei4. The direct spinothalamic pathway ends in the thalamus and it is responsible for
the discriminatory aspects of pain, such as location, intensity and nature. Cells in the
more dispersed spinoreticulothalamic system are probably involved in the arousal for
painful stimulus and reflex. The ascending pathway depicted above can be suppressed by
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a descending analgesic pathway that is, in part, mediated in the spinal cord, rich in opioid
receptors and endogenous opioid peptide agonists. Other areas that are involved in the
suppression of nociception (perception of pain) include periaqueductal gray, medullary
raphe and thalamus, which also contain large amounts of opioid receptors and
endogenous opioid peptides4,32. A more detailed discussion of the effects of opioid
receptors and endogenous opioid peptides will be given in subsequent sections.
Pain can be classified according to its nature: somatic pain and neuropathic pain.
Somatic pain can be described as well-localized, when the location is easily pointed by
the patient, and visceral pain, when pain is diffused, e.g. myocardial pain which is usually
referred to the left arm and shoulder. Neuropathic pain arises from injury or changes in
sensory pathways in the periphery or in more central structures that include exaggerated
response to noxious stimulus (hyperalgesia) or touch (hyperesthesia), spontaneous
burning or aching sensation (dysesthesia) and painful sensation from non-painful
stimulus (allodynia)4.
As old as attempts to explain the origins of pain are the methods to alleviate it.
Egyptian papyri describe ceremonies and rituals as well as vomiting, sneezing and
urinating as therapeutic strategies aimed to expel the bad spirits that caused pain. The
Roman physician Galen in the second century recommended theriac, a mixture that
included opium, saffron, cinnamon, rhubarb, pepper and ginger mixed with wine and
honey2. In the Middle Ages ointments containing opium and mandrake as well as theriac
were used to treat pain. Willow bark extracts have also been used since antiquity as
source of salicylates for the treatment of pain caused by inflammation. In the 19th
Century, the discovery of cocaine and its industrial production gave rise to a widespread
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use of the drug as a local anesthetic and stimulant. Electricity produced by electric fish
was used by Greeks and Romans for treatment of rheumatoid arthritis, headaches and
other types of chronic pain. After the development of techniques to produce and
accumulate electricity in the 18th and 19th centuries, a better understanding of the
relationship between electricity and the neurophysiology of pain gave opportunities to
modern explanations of electrotherapy to alleviate pain such as TENS (transcutaneous
electric nerve stimulation), SCS (spinal cord stimulation) and DBS (deep brain
stimulation)1.
Different causes of pain require distinct remedies. Alleviation of mild and
moderate pain can generally be achieved with non-narcotic analgesics such as aspirin,
acetaminophen or ibuprofen. Nevertheless, one of the most efficacious ways to treat
intense and chronic pain is the use of narcotic analgesics such as morphine and its
derivatives32.
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2. Poppy, opium and morphine
The use of opium for its pain relief and euphoric properties has been known for
centuries. Ancient Babylonians knew over 6000 years ago the psychological effects of
the extracts of the poppy plant (Papaver somniferum L.) and related species of Papaver
genera. Sumerian clay tablets dated about 3000 BC described the cultivation and opium
extraction from poppy plants, which they called "joy plant". Since the third century BC
opium has been used to assuage pain and promote sleep. Gastrointestinal problems such
as dysentery and diarrhea were also targeted by opium5. The word opium is derived from
"opos" and "opion", Greek names for juice and poppy juice respectively, whereas
morphine comes from Morpheus, the Greek god of dreams and sleep. Opium found its
way to Europe as a part of several formulations like laudanum, popularly useful for
treating plague. Historically associated with China, where by the end of the 17th century
25 percent of the population was smoking opium, the plant was widely cultivated in India
and smuggled into China. Although prohibited in China, in the 19th century British opium
traders had the monopoly of transportation, which led to two wars between these nations.
In order to control opium production, the International Opium Commission was created
in 1909 and by 1924, sixty-two countries were participating in agreements to decrease
opium production. Laws regulating importation, exportation, sales and distribution for
medical and scientific purposes were passed afterwards by signatory countries of the
League of Nations. Nowadays, international opium regulation is carried out by the
International Narcotics Control Board of the United Nations, with India being the larger
supplier of world demands. In the United States opium is considered a pharmaceutical
necessity and it is designated as Schedule II by the Drug Enforcement Agency6.

5

The dried latex exuded from immature poppy capsules is composed of about 12%
morphine and other alkaloids such as codeine (0.7 - 5%) , thebaine (0.1 - 2.5%) (Figure
1), papaverine (0.5 - 1.5%) and noscapine (1 - 10%)7, but some crops can produce
morphine in concentrations as low as 0.03%.

More than 40 alkaloids have been

identified which are normally classified into 12 main groups: benzylisoquinolines,
benzyltetrahydroisoquinolines,
morphinanes,

protopines,

proaporphines,
protoberberines,

aporphines,
berberines,

promorphinanes,
phtalideisoquinolines,

rhoeadine/papaver-rubines and benzophenanthridines8. Morphine was first isolated in
1804 by Sertüner, a pharmacist in Germany, but its structure was first elucidated more
than a century later in 19259. Albeit the complicated pentacyclic skeleton of
morphinanes, the first laboratory synthesis of morphine was achieved by Gates et al. in
195210. Although a number of synthetic studies and total syntheses of have been reported
to date11, industrial scale production of morphine and its derivatives are not considered
economically advantageous and therefore the plant is still the major source of opium
alkaloids7.

Figure 1 - Morphinan alkaloids.
Benzylisoquinoline alkaloids are a structurally diverse group of nitrogencontaining secondary metabolites comprised of approximately 2500 identified
substances, including morphinan alkaloids12. Opium alkaloids are biosynthetically
6

derived

from

the

aromatic

amino

acids

phenylalanine,

tyrosine

and

3,4-

dihydroxyphenylalanine, which in turn are obtained via the shikimic acid pathway in the
plant8 (Figure 2).

Figure 2 - Benzylisoquinoline alkaloid biosynthesis. 4-HPAA, p-hydroxyphenyl
acetaldehyde; TYDC, tyrosine decarboxylase; NCS, (S)-norcoclaurine synthase; 6'OMT,
(S)-norcoclaurine 6-O-methyltransferase; CNMT, (S)-coclaurine N-methyltransferase;
NMCH, (S)-N-methylcoclaurine 3'-hydroxylase (CYP80B subfamily); 40OMT, (S)30hydroxy N-methylcoclaurine 4'-O-methyltransferase; DRS, 1,2-dehydroreticuline
synthase; DRR, 1,2-dehydroreticuline reductase. (Adapted from ref. 12)

Despite the fact that poppy-derived opiates are major drugs of abuse with an illicit
market totaling around 4.8 million kilograms annually7, production of morphine
derivatives is only economically feasible by obtaining morphinan compounds through
7

plant cultivation. The majority of morphine naturally obtained from the poppy plant is
used in the production of codeine, which is present in the opium extract in low quantities
and is medically employed as a mild analgesic and cough suppressant. However, simple
O,O-diacetylation of morphine affords the highly addictive and illegal heroin. Although
illicit poppy production might be difficult, if not impossible to eradicate, genetically
engineered or mutagenized plants that give low morphine levels and are rich in codeine,
thebaine and oripavine content might be useful to circumvent the problem of heroin
manufacturing. Indeed, thebaine and oripavine are the starting materials for the synthesis
of valuable and powerful drugs in the market such as oxycodone (OxyContin),
buprenorphine (Subutex), naloxone (Narcan) and natrexone (ReVia)13. One of the key
enzymes necessary to biosynthesize morphinan alkaloids is salutaridine reductase (SalR),
which is a member of a class of short chain dehydrogenase/reductases overexpressed in
Papaver species (Figure 3)12. Studies have demonstrated that gene knockout of codeinone
reductase (COR1 - enzyme that converts condeinone to codeine and morphinone to
morphine) may be used for metabolic engineering of the opium poppy, circumventing the
biosynthesis of morphine and codeine, but maintaining the levels of other useful
morphinanes such like thebaine7.

8

Figure 3 - Morphinan alkaloids biosynthesis. SalSyn, salutaridine synthase; SalR,
salutaridine reductase; SalAT, 7(S)-salutaridinol 7-O-acetyltransferase; THS, thebaine
synthase; CoR1, codeinone reductase 1 (Adapted from ref. 12).
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3. Opioid receptors and their actions
The concept that drugs, hormones and neurotransmitters perform their functions
by binding to highly specific sites called receptors was developed in the twentieth
century. Specific receptors that mediate opioid actions were postulated based on the
stereospecificity of analgesic compounds and on the observation that minor structural
changes resulted in substances that can antagonize the action of opioids. By the 1970's,
the first endogenous opioid peptides were isolated and sequenced. These peptides were
named enkephalins, dynorphins, β-neoendorphin, β-endorphin, dermophins and
deltorphins. In 1973, Simon et al. described the highly specific binding of radiolabeled
etorphine (an opioid with a molar potency of 3200 greater than morphine14) in rat brain
homogenate supporting the existence of opioid receptors15. In same year, other groups
corroborated independently these findings in mammalian brain (Pert and Snyder;
Terenius)18. The concept of multiple opioid receptors rose after observations of the
actions of opioid agonists, antagonists and mixed agonist-antagonists. Neurophysiologic
observations in the dog spinal cord led to the proposal of three opioid receptors, named in
Greek letters after the drugs used in the studies: μ (for morphine, which induces
analgesia, miosis, bradycardia, hypothermia), κ (for ketocyclazocine, which causes
miosis, general sedation, depression of flexor reflexes) and σ (for SKF 10,047 or Nallylnormetazocine, which induces mydriasis, increased respiration, tachycardia and
delirium). A fourth type of opioid receptor was proposed after observing the effects of
opioid peptides in the mouse vas deferens and named δ (for deferens). After observations
that the σ-receptor is non-opioid in nature, there are thus three main types of
pharmacologically defined receptors: μ, δ and κ. Molecular biology approaches have also
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confirmed their existence mid-1990's by cloning, with binding and functional properties
compatible with their identities. In addition to the well-established three types of opioid
receptors, an orphan opioid receptor-like (ORL1) receptor was cloned. Although the use
of Greek letters is generally accepted by pharmacologists, molecular biologists usually
employ DOR, KOR, MOR, meaning delta, kappa and mu opioid receptor respectively.
To complicate the matter, the International Union of Pharmacology has proposed that the
receptors should be numbered after the chronological order of their cloning and
sequencing: OP1, OP2 and OP3 for δ-, κ- and μ-receptor respectively17. The three classes
of receptors can be further subdivided into their subtypes and their analgesic action
localization. Spinal and supraspinal antinociception is mediated by δ2 and κ1; spinal
analgesia is produced by activation of μ2; supraspinal analgesia is caused by μ1 and κ316.
Opioid receptors are not only present in the central nervous system, but also at the
periphery: preparations of isolated guinea pig ileum and the vas deferens from mouse, rat,
rabbit and hamster are routinely used for pharmacological assays of opioid receptors17. In
the central nervous system, there are regional variations: binding of [ 3H]naloxone (a
compound that blocks opioid action) is almost negligible in the cerebellum, but it is very
high in the corpus striatum. The dissection of monkey brain revealed even more drastic
variations that could explain the pharmacological actions of opioids. Receptors are
present in the periaqueductal gray, where electrical stimulation produces analgesia that is
antagonized by naloxone. The density of receptors in the medial thalamus, which takes
the 'emotional' components of pain to the cerebral cortex, is almost four times higher than
in the lateral thalamus, which conveys the 'pin prick' pain sensation that is not influenced
by opiates18.
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Opioid receptors belong to the large family of rhodopsin-like G-protein (guanine
nucleotide binding protein) coupled receptors (GPCR), with an overall amino acid
sequence identity of 60% for all three types of receptors. GPCRs are the most widespread
of several family of receptors, controlling virtually all known physiological functions in
mammals19. It is estimated that half of the drugs in the market act on GPCRs. Interesting
noting is that this receptor superfamily can bind to a broad range of substances, including
monoamines, nucleotides, amino acids, peptides, proteins and pherormones. This class of
receptors are also referred to as seven-transmembrane receptors (7TM), since their amino
acid sequence crosses the membrane seven times to make the connection between the
intracellular and extracellular medium20. The odd number of transmembrane spanning
domains place the N-terminal and C-terminal portions of the receptor protein on opposite
sides of the membrane, allowing ligand binding and glycosylation at the extracellular Nterminal and phosphorylation and palmitoylation at the intracellular C-terminal for
desensitization and internalization. The versatility of functions may be explained by the
fact that the seven transmembranes form six loops, offering the core sufficient size for
contact sites, specificities and regulatory mechanisms21. Upon ligand binding to the
receptor, the signal is transduced by guanine nucleotide binding proteins (G-proteins) that
are coupled to the receptor. The G-protein is a trimeric protein, consisting of α-, β- and γsubunits. Conformational changes caused by ligand binding catalyzes the hydrolyzation
of GTP to GDP in the α-subunit, which leads to its dissociation from the β- and γsubunits. This process modulates downstream effectors such as adenylate cyclase
inhibition that occur during opioid activity22. Other common actions include activation of
a potassium conductance, inhibition of calcium conductance and inhibition of

12

neurotransmitter release (Figure 4). More recent observations also include activation of
protein kinase C, release of calcium from extracellular stores and activation of the
mitogen-activated kinase cascade23. All three types of opioid receptors conserve sequence
similarity in rat mainly in the TM2 (transmembrane 2), TM3, TM7, the first extracellular
loop, the second and third as well as the fourth intracellular loops, whereas TM1, TM4,
TM5, TM6, the second and third extracellular loops are less conserved 24. An interesting
property of GPCRs is that they can combine to form new functional structures such as
homodimers (two receptors of the same type) and heterodimers (two receptors of
different types). It has been observed that heterodimerization of κ-δ-opioid receptors
modulates their function in a way that is distinct from the properties of single receptors.
This heterodimer has decreased affinities for their selective ligands, however synergistic
functional responses can be elicited by selective agonists acting cooperatively25.
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Figure 4 - Illustration of the effects that occur after opioid activation. Three primary
classes of effectors include inhibition of adenylyl cyclase, inhibition of vesicular release
and interactions of different ion channels (adapted from reference 23).
Most opioids have moderate selectivity among different types of opioid receptors,
eliciting similar pharmacological responses upon their stimulation. Nonetheless, in the
past 20 years, techniques such as receptor cloning, knockout animals and antisense
models have helped to investigate their actions separately. Generally, activation of all
three major classes of opioid receptors produces analgesia, but other agonist actions vary
depending on the receptor type. Euphoria, slow gastrointestinal motility, respiratory
depression (in volume), immune suppression and emesis are related to activation of μopioid receptors, whereas activation of δ-opioid receptors brings about respiratory
depression (rate) and immune stimulation. While μ-opioid receptor stimulation is
rewarding, inducing euphoria, the effects upon κ-opioid receptors are sometimes the
14

opposite. Indeed, besides producing sedation, miosis and diuresis, κ-agonists cause
dysphoria and avoidance in animals and humans32,34. Increased food intake is also
affected by administration of μ-, δ- and κ-opioid receptors agonists, whereas antagonists
such as naltrexone and naloxone are able to diminish feeding response26. Other important
actions of opioids include antitussive properties as well as undesirable tolerance and
dependency.

15

4. Opioid ligands
Opioid ligands, whether they elicit or block pharmacological action, can be
basically divided into three groups. The first group contains natural products and semisynthetic derivatives such as morphine and heroin respectively. Totally synthetic
compounds are part of the second group, which may have little or no resemblance to the
natural and semi-synthetic structures. The last group comprises naturally occurring (or
endogenous) and synthetic peptides36.
4.1. Non-peptide ligands
The first and second group of opioids can be aggregated into the non-peptide
opioids. The prototypical opioid agent is the natural product morphine, from which most
of the clinically available opioid analgesics are derived by either semi-synthesis or
simplification of the natural product template. The first synthetic opioid obtained was the
heroin (3,6-diacetylmorphine) in 1874 through semi-synthesis from morphine. Heroin
was one of the first examples of a prodrug aimed to reduce the inconveniences of
respiratory depression and dependency of morphine, but it soon became apparent that
these claims were unfounded. Synthetic opioids can be broadly grouped into 4,5αepoxymorphinans,

morphinans,

benzomorphinans,

phenylpiperidines

and

phenylpropylamines. The progressive simplification from the morphine scaffold to
morphinans and benzomorphinans as well as phenylpiperidines to phenylpropylamines
illustrates how other classes of opioids were obtained (Figure 5)27.
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Figure 5 - Illustration of the progressive simplification of morphine-related drugs
(Adapted from reference 27)
It is beyond the scope of this work to summarize structure-activity of all classes of
opioid analgesics. However the basic requirements for opioid activity of morphine and its
derivatives proposed by Beckett and Casy can be briefly described in Figure 6. At
physiological pH, the nitrogen atom is protonated and binds to the receptor anionic site.
The rigid piperidine ring is accommodated in the cavity on the receptor binding site,
whereas the phenolic ring adhere to the flat surface of the binding site. On the other hand,
the synthetic (+)-morphine is devoid of opioid activity since it cannot bind to the receptor
in the same way the natural (-)-morphine does32,36.
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Figure 6 - The opioid binding site model. (Adapted from references 32 and 36)
Since the synthesis of heroin, the first semi-synthetic opioid, numerous structural
modifications have been made to several portions of the morphine molecule. However,
alterations have been concentrated in three regions: the phenol at position 3, the C ring
and the nitrogen (Figure 7). Changes in the phenolic hydroxyl usually decrease opioid
activity. Either methylation (codeine) or acetylation (heroin) diminishes opioid receptor
activity; however codeine retains around 10% of morphine potency due to in vivo
demethylation to morphine, whereas heroin is twice as potent as morphine since its fast
penetration into the blood-brain barrier and further hydrolysis to morphine. Oxidation or
etherification at the 6-position as well as saturation of the C ring (7-8 position) increase
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activity. Finally, demethylation of the basic nitrogen decreases activity, while
introduction of bulky groups at this position leads to antagonists28.

Figure 7 - Structure of morphine.
The basic three-point requirements for opioid binding as well as a brief structureactive relationship of the morphine analogues have been previously mentioned. Another
important aspect worth to be brought up is how different compounds bind preferably to
distinct opioid receptor types. While common structural features of compounds interact
with conserved residues among the three main classes of opioid receptors, uncommon
moieties interact with amino acid residues that are dissimilar. This can be explained by
the “message-address” concept, which in a nutshell states that the common portion of
ligands represents the “message”, whereas the variable moiety acts as the “address”, thus
conferring selectivity. This concept can be illustrated by comparing the high affinity
nonspecific opioid antagonist naltrexone against the κ-selective 5-guanidinylnaltrindole
(GNTI) and the δ-selective naltrindole (NTI) in Figure 8. In the case of nonspecific
opioids naltrexone and naloxone, both satisfy the 3-point requirement model (Figure 6)
“message”, but the “address” locus is lacking. The obvious difference regarding the δselective opioids naltrindole and 7-spiroindanyloxmorphone (SIOM) is the presence of a
hydrophobic group, indole and spiroindane respectively, which acts as the “address”
portion, therefore giving binding selectivity. Addition of a second basic moiety in the
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“address” site of 5-guanidinylnaltrindole (GNTI) and norbinaltorphimine (nor-BNI)
provides selectivity toward κ receptors, implicating the formation of an ionic bond with a
glutamate residue (Glu VI:23) unique to this receptor.

Unfortunately, the message-

address concept cannot be verified with μ-selective compounds such as morphine and the
irreversible antagonist β-funaltrexamine (β-FNA) because they lack a common “address”
site29.
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Figure 8 - Message-address moieties of nonspecific (naltrexone and naloxone),
δ-selective (NTI and SIOM), κ-selective (GNTI and nor-BNI) and μ-selective (β-FNA)
opioids.
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Pain is the major reason for a patient to seek medical advice, hence analgesics
represent a huge therapeutic market of over $70 billion in the United States. Opioid sales
in 2007 were $8.4 billion in the US, which constitutes 70% of the global market for this
drug class. Sales of opioids have been growing 13% on average since 200130. There are
about 20 opioid drugs available on the US market that are sold with various trade names
and routes of administration, ranging from patches to intravenous injections. Besides the
naturally occurring morphine and the cough suppressant codeine, commercially available
drugs that represent the five main classes (Figure 5) of non-peptide opioids are depicted
in Figure 931.

Figure 9 - Commercially available analgesics representing the five main opioid classes.

4.2. Peptide ligands
Scientists had postulated that morphine and other synthetic opioids were not the
natural ligands for opioid receptors and that other analgesic substances must exist in the
22

brain. In the mid-1970's, the first endogenous opioid peptides were discovered and
collectively named as endorphins, which is a combination of the words endogenous and
morphine. Endogenous opioid peptides are produced from parts of large precursor
proteins and the three major types of opioid peptides have their own precursor protein.
Proopoimelanocortin is the precursor for β-endorphin, whereas proenkephalin A is the
precursor for met-enkephalin and leu-enkephalin. The pro-opioid peptide proenkephalin
B is the precursor for dynorphin and α-neoendorphin. All pro-opioid peptides are
synthesized in the cell nucleus and transported to the nerve terminals where they are
released. Proteases hydrolyze the pro-opioid peptides into their active form by
recognition of a double basic amino acid before and after the opioid peptide sequences 32.
The analgesic action of peptides is short, since they are rapidly degraded by several
peptidases such as aminopeptidases and dipeptidyl peptidases33. Although selectivity
towards distinct receptor types is generally considered weak, peptides in the enkephalin
and β-endorphin groups bind preferably to μ- and δ-receptors, whereas dynorphin is more
selective towards κ-receptors34. The precursors, amino acid sequences and affinities of
these endogenous peptides are shown in Table 1.
Table 1. Mammalian endogenous ligands of opioid receptors35
Precursor

Endogenous
peptide

Amino acid sequence

Affinity

Pro-enkephalin

[Met]-enkephalin
[Leu]-enkephalin

Tyr-Gly-Gly-Phe-Met
Tyr-Gly-Gly-Phe-Leu
Tyr-Gly-Gly-Phe-Met-Arg-Phe
Tyr-Gly-Gly-Phe-Met-Arg-Gly-Leu
Tyr-Gly-Gly-Phe-Met-Arg-Arg-Val-NH2
Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr-LeuPhe-Lys-Asn-Ala-Ile-Ile-Lys-Asn-Ala-Tyr-Lys-Lys-Gly-Glu
Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asp-Asn-Gln
Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile
Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr
Tyr-Gly-Gly-Phe-Leu-Arg-Lys-Tyr-Pro-Lys
Tyr-Gly-Gly-Phe-Leu-Arg-Lys-Tyr-Pro
Tyr-Gly-Gly-Phe-Leu
Tyr-Pro-Trp-Phe-NH2
Tyr-Pro-Phe-Phe-NH2

δ, μ

Proopiomelanocortin
Pro-dynorphin

Unknown

Metorphamide
β-endorphin
Dynorphin A
Dynorphin A(1-8)
Dynorphin B
α-neoendorphin
β-neoendorphin
[Leu]-enkephalin
Endomorphin-1
Endomorphin-2
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(δ>> μ)
μ= δ
κ, μ, δ
(κ>> μ,
δ)
μ

Although opioid peptides never became marketed drugs due to their poor
pharmacokinetic properties (very short half life and inability to cross blood-brain barrier),
several strategies to improve stability have been attempted such as incorporation of
unnatural D-amino acids, methylated amino acids and conversion of the carboxylic acid
terminal to amide as well reduction to its alcohol derivatives. Inclusion of β-amino acids
and cyclic peptides as well as formation of peptide dimers and oligomers have also been
tried. While in vivo stability of opioid peptides is the concerning issue, peptide analogues
have been widely employed as pharmacological tools in opioid receptor research. For
example, radiolabeled DAMGO (Tyr-D-Ala-Gly-N-MePhe-Gly-OH) is used as high
affinity μ-agonist in binding studies, whereas the cyclic pentapeptide DPDPE (Tyr-DPenicillamine-Gly-Phe-D-Penicillamine [2,5-dissulfide bridge]) is considered the
prototypical δ-selective opioid peptide36.
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5. Opioid tolerance and dependence
In addition to respiratory depression, the most serious adverse effect of opioid
agonists administration is the development of tolerance and dependence. For a long time,
it was hypothesized that repeated administration of certain drugs can provoke longlasting changes in the brain, leading to abuse. In order to investigate the neurophysiologic
causes of addiction, the National Institute on Drug Abuse (NIDA) was created in 1974,
which then became part of National Institutes of Health (NIH) in 1992 37. Tolerance refers
to a state of diminished responsiveness to a drug, whereas physical dependence arises
from the cessation of drug administration that leads to withdrawal syndrome;
administration of the drug is therefore necessary in order to reverse these effects 38.
Besides being a devastating disease that can lead to many personal problems and death,
addiction also puts a huge burden on public health. The American Psychiatric
Association defines substance abuse in the Diagnostics and Statistical Manual of Mental
Disorders (DSM-IV) as: "[A] maladaptive pattern of substance use with physiological
addiction, impaired control of substance taking, and/or adverse consequences (e.g.,
problems in social or occupational functioning)."39.
The potential factors connected to addiction or abuse are related to dose, route of
administration, co-administration with other drugs, context of use and expectations.
Particularly, pain relievers are the most abused prescribed drugs, increasing from 628,000
initiates in 1990 to 2.4 initiates in 200140. The psychopharmacological elements
underlying drug-seeking behavior are as complicated as shown in Figure 10.
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Figure 10 - Factors that influence the psychopharmacological effects of drug abuse.
5.1. Molecular mechanisms of tolerance and dependence
In spite of the fact that almost 40 years have passed since the creation of NIDA,
the mechanism of addiction is not yet fully understood, though enormous progress has
been achieved. At the biochemical level, the binding to opioid receptors brings about the
inhibition of adenylate cyclase, the enzyme responsible for the conversion of cyclic
adenosine monophosphate (cAMP) from adenosine triphosphate (ATP). Acting as a
second messenger, cAMP carries the signal from extracellular binding to intracellular
effectors. Upon repetitive exposure, the late compensatory increase of adenylate cyclase
counteracts opioid inhibition and rises far above the normal levels. Adenylate cyclase
induction is responsible for opioid tolerance and withdrawal symptoms that lead
dependence41. An important consequence of adenylate cyclase up-regulation is the

26

increase of cAMP-dependent protein kinase (PKA) responsible for the phosphorylation of
cAMP response element binding protein (CREB). Functioning as a transcription factor,
CREB alters gene expression that regulates numerous cellular processes involved in
tolerance and dependence42. It is also worth mentioning that a cascade of events upon
receptor activation promotes receptor desensitization and endocytosis. Following
endocytosis, receptors can be recycled and sent back to the membrane, encapsulated in a
vesicle or degraded. For recycled receptors, like μ-opioid receptors, endocytosis is the
first step toward resensitization. Tolerance and dependence of chronic morphine
treatment come from the fact that this opioid receptor does not induce endocytosis, thus
no resensitization takes place43.
5.2. Neuronal mechanisms of addiction
Basically, there are four brain circuits implicated in addiction: reward, motivation,
memory and control. They are linked to the different concepts: reward, internal state
(motivation/drive), learned associations (memory) and conflict resolution (control). In the
addicted brain, the inhibitory control of the prefrontal cortex is overwhelmed by the
augmented value of the drug in the reward, drive and memory circuits. The lack of
control participation favors a positive feedback among the three remaining circuits,
perpetuating drug consumption (Figure 11)44.
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Figure 11 - Proposed model of circuits involved with addiction in nonaddicted and
addicted brain44.
Functional changes in the mesolimbic dopaminergic (DA) neurons are caused by
Functional changes in the mesolimbic dopaminergic (DA) neurons are caused by
abrupt interruption of opioid administration, which leads to aversive effects like
dysphoria and anhedonia; therefore, for the addict, the urge to administer the drug again
is necessary to avoid these symptoms. Chronic use of opioids modifies the activity of the
nucleus accumbens (NAc), which is targeted by DA neurons and give feelings of
pleasure. Neurons from NAc project to the ventral pallidum and the ventral tegmental
area (VTA) and contain GABA, opioid peptides enkephalin and dynorphin as well as
substance P. It is thought that alterations in these neurons play a role in the negative
effects of opioid withdrawal. There are two parts in the NAc: the core may be involved in
drug-seeking behavior, while the shell is related to psychostimulant effects of drugs of
abuse. Other structure connected to the VTA is the prefrontal cortex, which is responsible
for behavioral control. The main neural effect of drugs of abuse is the stimulation of
dopaminergic neurons in the VTA that releases dopamine in the NAc, contributing to the
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reward response. Besides the NAc and VTA, structures that contain opioid peptides and
may be responsible for opioid reward are: locus coerelus, amygdala, substantia nigra,
periaqueductal gray and arcuate nucleus37,42,45.
5.3. Treatment of opioid dependence
The first step in dependence treatment demands identification of the opioid
abuser, whether the patient is a street drug user or taking a prescribed opioid. In 2008,
there were a total of 1,132 facilities offering opioid treatment programs46. Treatment
options include counseling and pharmacologic therapies such as maintenance with opioid
agonists (e.g. methadone) as well as detoxification with opioid antagonists (e.g.
naltrexone and naloxone)47. Most medications used to treat opioid addiction interact with
μ-receptors, like the abused opioids themselves, but their actions last longer. Methadone
and L-alpha acetylmethadol (LAAM) are full μ-agonists with different durations of
action, whereas buprenorphine is a partial agonist48. Non-opioid therapies include
clonidine, an α2-adrenergic agonist that relieves up to 85% of withdrawal symptoms 49.
Another non-narcotic α2-adrenergic agonist closely related to clonidine that is currently in
phase III clinical trials is lofexidine50,51. Along with psychosocial interventions, there are
basically two pharmacological approaches used to treat opioid addiction: detoxification
and maintenance.
Although not life threatening, abrupt termination of opioid use leads to almost
unbearable withdrawal symptoms, including chills, sweating, diarrhea, nausea, anxiety,
irritability and insomnia. In order to reduce these symptoms, clonidine and other α2adrenergic agonists are employed with fewer side effects than methadone and patient
participation, though clonidine has been linked to sedation and hypotension52. Besides
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being used to avoid death by overdose, opioid antagonists (naloxone and naltrexone) can
also be utilized along with deep sedation or anesthesia for rapid recovering from
withdrawal side effects53. Another method of detoxification is called tapering, which is
the process of substituting the abused opioid for another agonist (methadone or
buprenorphine) and then slowly decrease the dose52. Methadone is the oldest drug used
for tapering and it still considered the drug of choice (frequently in conjunction with
buprenorphine) in most opioid addiction treatment programs46.
The main objectives of maintenance treatments are to decrease craving and
undesired withdrawal symptoms as well as avoid euphoria by carefully dosing the opioid
agonist, therefore reducing drug-seeking behavior linked to overdose risk, HIV infection
and criminal activity. Despite the fact that individuals undergoing opioid maintenance
treatments are still physically addicted, these programs are aimed to reduce drug-related
activities and allow patients to transition into drug-free programs52. Since the 1960’s,
methadone has been used for maintenance treatment and it is the most well studied, first
line drug for these therapy. However, LAAM and buprenorphine have two to three times
the duration of methadone and they can be administered three times a week. The longer
duration, besides providing fewer plasma level fluctuations between doses, may be
advantageous over methadone in maintenance treatment programs54. Drugs currently
used for treatment of opioid dependence are shown in Figure 12.

30

Figure 12 - Substances used for opioid addiction treatment: full opioid agonists
(methadone and LAAM), partial agonist (buprenorphine), antagonists (naltrexone and
naloxone) and α2-adrenergic agonists (clonidine and lofexidine).

5.4. Treatment of opioid dependence and Mitragyna speciosa
Although several pharmacological and psychological treatment approaches are
effective, it is clear that, giving the relapsing nature of opioid addiction, many individuals
will return to an opioid-dependent lifestyle. In order to prevent the negative outcomes
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related to opioid addiction, it is imperative to search for new ways to help addicted
patients to overcome opioid dependence. The scope of this work is to study novel
compounds based on the alkaloids present in Mitragynine speciosa, also known as
kratom. Descriptions dated back to as early as 1897 show that this plant was indicated
for treating pain and opium abstinence syndrome. Indeed, a recent case report describes
that a patient who abused hydromorphone was able to manage the intensity of opioid
withdrawal by ingesting kratom tea55. This finding is also corroborated by several
individuals depicting modulation of opioid withdrawal by ingesting kratom56.
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6. Mitragyna speciosa and its alkaloids
Mitragyna speciosa Korth is a tree member of the Rubiacea family that is
indigenous to tropical Southeast Asia. Popularly known as kratom in Thailand and BiakBiak in Malaysia, the leaves have been consumed by natives to induce opium-like effect
and coca-like stimulant. The plant has been also used as an opium surrogate to decrease
withdrawal syndrome in opioid abusers. Although it has been outlawed in those countries
as well as in Australia, people still ingest the leaves by brewing tea, chewing or
smoking57. In the United States leaves, extracts and powders are legally available through
an increasing number of websites. Descriptions of preparations and effects of Kratom are
widely available online through a growing number of testimonials58,59.
Mitragynine is the major constituent of M. speciosa leaves, making up to 66% of
the total alkaloidal extract. Other Corynanthe-type alkaloids present in the crude extract
are paynantheine (8.6%), speciogynine (6.6%) and speciociliantine (0.8%). Another
minor plant component (2%) of interest regarding opioid activity is 7α-hydroxy-7Hmitragynine57. Figure 13 shows the structures of these five alkaloids. Biosynthetically,
corynanthe-type alkaloids are derived from a Mannich-like reaction between the
ethylamine portion of tryptamine and a keto acid to give the tetrahydro-β-carboline
system60.
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Figure 13 - Structures of alkaloids present in Mitragyna speciosa.
Studies have shown that mitragynine has analgesic and antitussive properties
comparable to codeine, without producing respiratory depression in comparison to this
classic opioid. In vitro assays using membranes of guinea-pig brain showed that
mitragynine binds preferably to μ-opioid receptors, with a pKi of 8.14 ± 0.28 as compared
to 8.46 ± 0.28 of morphine in saturated radioligand ([3H]DAMGO). Preparations of
electrically-stimulated contractions in guinea-pig ileum displayed an inhibitory activity of
95% relative to morphine, however it showed a relative potency of only 26%.
Antinociceptive activity in the tail-flick test in mice by intracerebroventricular
administration of mitragynine revealed an estimated EC50 value of 60 nmol/mouse,
whereas the average value for morphine was 3.2 nmol/mouse. On the other hand, 7hydroxymitragynine showed a relative potency to morphine of over 10-fold, while
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maintaining its relative inhibitory activity of 99% in the electrically-stimulated guineapig ileum test. Moreover, antinociceptive activity 7-hydroxymitragynine in both tail-flick
and hot-plate test in mice after either oral or subcutaneous administration was higher than
of morphine. In fact, 7-hydroxymitragynine antinociceptive effect was elicited after oral
administration of 5 – 10 mg/kg in the tail-flick test in mice, whereas morphine did not
produce any analgesia at 20 mg/kg p.o. in either assay57,61.
Mitragynine obtained by our group was also subjected to binding assays; however
discrepancies were observed when compared to studies described in the previous
paragraph. Although there is an agreement that its affinity is higher for μ-opioid
receptors, the Ki value obtained was 81.97±5.49 nM, around 10-fold greater than the
result observed in the previous study (7.24±0.52 nM). Opioid receptors are not the solely
targets of mitragynine; this alkaloid also has affinity for other receptor types (Figure 14).
It is worth noting that mitragynine binds to α2-adrenergic receptors, which might explain
its opioid withdrawal attenuation property, since this receptor is agonized by clonidine,
an α2-adrenergic agonist.

Figure 14 - Percentage of inhibition by mitragynine among different receptors.
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6.1. Mitragynine SAR
Some known structure-activity relationships (SAR) in electrically-stimulated
guinea-pig ileum preparations are depicted on Figure 15. The 9-methoxy group is optimal
to affinity and, as discussed above, 7-hydroxylation substantially increases opioid
activity. Basic nitrogen is also required, since N-oxidation leads to inactivity.
Speciociliantine, a C3 stereoisomer of mitragynine, has very low potency compared to
mitragynine (13-fold decrease), which means that the four-ring structure must be on the
same plane (S-configuration) in order to optimize opioid activity61.

Figure 15 - In vivo mitragynine SAR.
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7. Rationale
There are basically two different classes of molecules that were envisioned based
on

mitragynine:

phenylpiperdine

(including

phenylaminopiperidines

and

phenylamidopiperidines) and tetrahydro-β-carboline derivatives. The idea was to simplify
and increase flexibility of molecules in order to create novel opioid-active compounds
and potentially comprehend the requisites necessary for opioid receptor affinity and
activity. In the field of morphine analogue development, this approach has led to several
marketed compounds with potent opioid activity that possess minimal structural
requirements for binding and activity62. Tetrahydro-β-carboline derivatives are also to be
explored for their tetracycle similarity to mitragynine and the ability to synthetically
eliminate some functional groups present in this alkaloid.
7.1. Phenylpiperidines, phenylaminopiperidines and phenylamidopiperidines
Initially, in order to investigate the pharmacophore moiety that may be involved
in the opioid action of mitragynine, simple compounds 1 - 4 were proposed based on the
backbone of mitragynine as show in Figure 16.

Figure 16 - Simple phenylaminopiperidines. Common features in red.
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In order to investigate the pharmacophore responsible for the opioid activity of
mitragynine, some moieties were proposed based on the structure of this alkaloid. One of
the envisaged structures is 5, which resembles mitragynine, but it is designed to alleviate
the constraints on rings A and C (Figure 13). Since all four rings of mitragynine form a
planar and rigid structure, it was thought that a more flexible molecule could have more
contact points with opioid receptors. The highlighted scaffold is depicted in blue in
Figure 17.

Figure 17 - Mitragynine and proposed phenylaminopiperdine. Common features in blue.
Fentanyl and structurally related analgesics in the phenylpiperidine family such as
carfentanyl and sufentanyl as well as meperidine are potent μ-opioid agonists. In fact
only 0.12 mg of fentanyl is required to produce the same analgesia as 10 mg of
morphine63. By combining some structural elements of mitragynine (blue) and fentanyl
(orange) along with remifentanil as shown in Figure 18, it was hypothesized that
compound 6 may have opioid activity.
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Figure 18 - Proposed phenylamidopiperidine based on mitragynine, fentanyl and
remifentanil.
A wide variety of 4-phenylpiperidines have been widely investigated for their
affinity for opioid receptors64. Taking this into account along with the structures of
mitragynine and its 7-hydroxy derivative, other structures were proposed as shown in
Figure 19. Compound 7 resembles the backbone of mitragynine (blue), whereas
compound 8 is similar to the structure of 7-hydroxymitragynine. Both structures were
planned having in mind the alleviation of constraint of rings A and C (Figure 13).
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Figure 19 - Mitragynine, 7-hydroxy-mitragynine and phenylpiperidines. Similarities are
in blue (mitragynine) and red (7-hydroxy- mitragynine).

7.2. Tetrahydro-β-carbolines
As

previously discussed,

phenylpiperidines,

phenylaminopiperidines

and

phenylamidopiperidines were planned to mimic mitragynine and its 7-hydroxy derivative,
while introducing flexibility on the backbone by removing rings A and C. Nonetheless, it
was thought necessary to explore smaller changes on the natural product structure. To
this end, tetrahydro-β-carbolines were proposed to closely resemble the four-ring
structure of mitragynine and explore smaller changes to elucidate some structure-activity
relationships. These modifications were concentrated on the 15-position of mitragynine
structure (Figure 13). Another compound of interest is 38, which is based on
hydroxylated 7-hydroxymitragynine, an alkaloid with in vivo antinociceptive properties
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in both tail-flick and hot-plate test higher than morphine. For the purpose of synthetic
simplification, the ethyl group was omitted as illustrated in Figure 20.

Figure 20 - Tetrahydro-β-carbolines based on mitragynine and 7-hydroxymitragynine.
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8. Synthetic strategies and discussion
The next section will be subdivided into two classes of compounds:
phenylpiperidines (inclunding phenylaminopiperidines and phenylamidopiperidines) and
Tetrahydro-β-carbolines. Schemes and reactions conditions as well as problems
encountered will be depicted and discussed. Furthermore, stereochemistry considerations
will be addressed in the end of this section.
8.1. Phenylpiperidines, phenylaminopiperidines and phenylamidopiperidines
The general strategy to obtain 2 – 4 is to first transform N-methyl-3-piperidinol
into its methanesulfonate ester and further react with the corresponding aniline derivative.
The overall yield for these reactions were very low (<2%) due to the difficulty of
sulfonate ester formation. Synthesis of the toluenesulfonyl and trifluoromethanesulfonyl
esters65 were attempted, but they also gave very low yields. To obtain the aniline of
compound 1, first the hydroxyl group of 4-nitroguaiacol was protected with the acetyl
group66, then the nitro group was reduced using palladium on carbon (10%) under
pressurized

hydrogen

atmosphere67,

which

was

reacted

with

N-methyl-3-

piperidinomethanesulfonyl ester.
As previously discussed, overall low yields were obtained with sulfonate esters.
In this case, reductive amination between m-anisidine and a piperidone was considered as
alternative route. First, the oxidation of N-methyl-3-hydroxypiperidine to the
corresponding ketone was tried through two different approaches: (a) oxidation by
aqueous sodium hypochlorite68, and (b) oxidation by using Dess-Martin periodinane69,
however both methods gave low yields (less than 7%).

Reductive amination was

primarily carried out using the readily available N-methyl-4-piperidone and sodium
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cyanoborohydride in acetonitrile at reflux or applying microwave radiation70. Formation
of the amine bond was only improved from less than 3% to 12% after employing the less
polar solvent 1,2-dichloroethane (DCE) at room temperature71.

Scheme 1. (a) AcOH, NaBH(OAc)3, DCE (b) H2 (55 psi), Pd/C, MeOH (c) K2CO3, r.t.
(d) LDA, methylformate, THF -78 ºC (e) p-TsOH, trimethyl orthoformate, MeOH, reflux
(f) t-BuOK, DMSO

The first step was carried out using m-anisidine and the readily available benzylprotected ketone: N-benzyl-4-piperidone71 (Scheme 1). The yield was considerably
higher as compared to the reductive amination described above, from 12% to 70%. Since
the desired amine bond is at 3-position relative to the piperidine ring, reductive
amination was accomplished using the commercially available N-benzyl-3-piperidone
hydrochloride, which was extracted to the corresponding base before reacting with manisidine. Reductive amination was also carried out using sodium triacetoxyborohydride
and acetic acid in 1,2-dichloroethane71 at room temperature for 72h, which after
purification gave a cleaner product according to NMR analysis with 50% yield.
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The next step consisted in the removal of the benzyl group. Several approaches
were used to deprotect the piperidine ring employing palladium on carbon and
ammonium formate or formic acid72 as sources of hydrogen in methanol. Zinc was also
used as catalyst along with ammonium formate in methanol at room temperature, but no
reaction took place after 45 hours. Even after irradiating with microwave at 80 ºC for
one hour, no change in TLC (Thin Layer Chromatography) was observed73. Another
method for debenzylation employed palladium on carbon and a mixture of ethanol and
cyclohexene under reflux for 24 hours74. Only after using palladium (10%) on carbon
under hydrogen atmosphere at 55 psi suspended in methanol, the reaction time was
reduced to 4h. The last approach also provided up to 85% yield after purification
through chromatography75.
Alkylation of the secondary amine formed after the elimination of the benzyl
group was attempted by reacting methyl 5-bromovalerate using potassium carbonate and
a phase transfer catalyst76 such as tetrabutylammonium iodide or bromide in DMF.
Different reaction temperatures ranging from room temperature to 55 °C were tried; yet
concomitant alkylation of the aromatic amine probably took place as a byproduct
according to mass spectroscopy. The formation of the this derivative could be
circumvented by not employing a phase transfer catalyst and simply using potassium
carbonate in DMF at room temperature, giving a yield of 53%.
In order to introduce the formyl group alpha to the ester 15, it was found
necessary to first protect the aromatic amine, as lithium diisopropylamine reacts with the
amino hydrogen, giving compound 16 according to mass spectroscopy (Scheme 2). This
should have been expected, since the aromatic amine is more acidic than the methylene

44

next to the carbonyl group. The first attempt to benzylate the amino group used benzyl
bromide in DMF and different bases (K2CO3 or KH)77; however it was observed through
TLC that formation of a quaternary amine in the piperidine ring took place. Introduction
of the benzyl group through reductive amination using benzaldehyde and NaBH(OAc)3
in acidic conditions was not successful. Protection of the aromatic amine was also
attempted using di-tert-butyl dicarbonate78, but the product recovered by flash
chromatography was the starting material. Carbamate protection using ethyl
chloroformate79 in DCE or DMF at temperatures up to 85 ºC was not successful after
several hours. Although some product was identified by mass spectroscopy, it was
observed by TLC that the yield was very low, even after addition of up to 15 equivalents
of ethyl chloroformate.

Scheme 2. LDA, THF, -70 °C. Unsuccessful introduction of the formyl group alpha to
the ester 15.
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The phenylamidopiperidine 6 based on structural similarities among potent
opioids such as fentanyl and remifentanyl as well as the alkaloid mitragynine (Figure 18)
was easily obtained as shown on scheme 3. Compound 15 was treated with propionyl
chloride and triethylamine in refluxing DCE under argon, yielding 95% after purification
by silica gel chromatography80.

Scheme 3. Propionyl chloride, Et3N, DCE, reflux.
Regarding the rationale depicted in Figure 19, the phenylpiperidine 7 was
obtained as shown in scheme 4. The tertiary alcohol 17 was obtained by transforming 2bromoanisole into the corresponding Grignard reagent and then adding N-benzyl-4piperidone, yielding 27% along with three byproducts81. Intramolecular elimination of
water using acidic condition in refluxing toluene yielded 56% of pale yellow oil (18).
Posterior debenzylation and olefin reduction was catalyzed by palladium under hydrogen
atmosphere to give the secondary amine 19. When compared to the conditions used to get
15, alkylation of the secondary amine 19 was improved both on yield (81%) and time (2
hours) by heating to 60 ºC and using NaHCO3 (20). Introduction of the formyl group
alpha to the ester was achieved by treating with lithium diisopropylamide in THF at
-70 ºC and then adding methyl formate. The product obtained (21) with 70% yield was a
mixture of aldehyde and enol tautomers, which was verified by both TLC and NMR
analysis. The three spots on the TLC are compatible to a mixture of the aldehyde form as
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well as two enolic geometric isomers. Taking into account the proton NMR spectrum, the
aldehyde form was predominantly present in a 2/3 ratio. As it will be described later in
the case of tetrahydro-β-carbolines, it was thought that in order to obtain the
methoxyacrylate 7, compound 21 would have to be converted to the acetal 22 and then
submitted to basic treatment with potassium tert-butoxide. Interestingly, the last step
could be circumvented by extending the reaction time and adding an excess of tosic acid
and trimethyl orthoformate, without affecting the yield (23%)82. Regarding the methyl
methoxyacrilate isomer, it was expected that the (E)-isomer was obtained83 due to the
high repulsion energy of oxygen atoms while in (Z)-configuration (4.46 kcal/mol
according to ChemBio3D software MM2 energy minimization).
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Scheme 4. (a) Mg, THF, I2 (b) p-TsOH, toluene, reflux (c) H2, Pd/C, EtOH (d) methyl 5bromovalerate, NaHCO3, DMF, 60 ºC (e) LDA, methyl formate, THF (f) TsOH,
trimethyl orthoformate, MeOH, reflux

Compounds 17, 23 and 24 (Scheme 5) where again prepared with similar yields as
previously described in Scheme 4. Nevertheless, it was found to be necessary to protect
the tertiary alcohol 24 to obtain 8, as two key steps are incompatible with this hydroxyl
group. First, formyl group introduction requires a strong base, lithium diisopropylamide,
which easily deprotonates the tertiary alcohol; second, tertiary alcohols readily undergo
intramolecular dehydration under acidic conditions, like the one employed to obtain the
methoxyvinyl moiety.
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Scheme 5. (a) H2, Pd/C, EtOH (b) methyl 5-bromopentanoate, NaHCO3, DMF, 60 ºC.
PG: protective group.
Since formation of the methoxyvinyl moiety requires the use of tosic acid, the
chosen protecting group would have to survive this condition. Silyl ethers are among the
most commonly used protective groups for the alcohol function, but are susceptible
toward acid hydrolysis84. Protection by the benzyl group was thought as an alternative, as
his ether are resistant toward acid hydrolysis. Nevertheless, by submitting compound 7 to
the deprotection conditions (H2, Pd/C in EtOH), it was observed that the methoxyvinyl
double bond underwent reduction according to mass spectroscopy. Another possible
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choice to protect the tertiary alcohol explored the advantage of the acidic stability of
methylthiomethyl (MTM) ether, which can be removed with the neutral mercuric
chloride84. The first method to introduce the MTM group in 24 employed DMSO and
acetic anhydride at room temperature85,86, which gave the protected MTM ether in minor
quantities along with the acetate ester and intramolecular water elimination product.
Besides the evidence by mass spectroscopy and TLC of MTM ether and byproducts
formation, the reaction mixture was submitted to deprotection using HgCl2 in
water/acetonitrile87, which gave back the starting material 24 (according to TLC). The
difficulty to introduce the MTM group to a tertiary alcohol was evident, as different
methods were attempted without success: (a) methylthiomethyl chloride, NaH, NaI,
THF87;

(b)

methylthiomethyl

chloride,

AgNO3,

triethylamine,

benzene86;

(c)

methylthiomethyl chloride, AgNO3, triethylamine, toluene. As the only method that
looked promising used dimethyl sulfoxide and acetic anhydride to form a sulfonium ion,
which then reacts with the hydroxyl group to give the MTM ether88, the rest of starting
material 24 was submitted to this procedure. However, the only compound obtained after
purification was the acetate ester 25. Scheme 6 exemplifies the different strategies
pursued to obtain the protected hydroxyl group by MTM ether.
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Scheme 6. (a) Ac2O, DMSO (b) Cl-CH2SCH3, NaH, NaI, THF (c) Cl-CH2SCH3, AgNO3,
Et3N, benzene, 60 ºC (d) Cl-CH2SCH3, AgNO3, Et3N, toluene, 70 ºC.

8.2. Tetrahydro-β-carbolines
The tryptamine 28 was obtained as shown in scheme 7. Commercially available
4-methoxyindole 26 underwent nitro olefination at 3-position with N,N-dimethylamino-2nitroethylene in trifluoroacetic acid89. Reduction of both ethylene and nitro groups in 27
was carried out employing lithium aluminum hydride in THF to give 28 with 15.5% yield
(two steps).

Scheme 7. (a) N,N-dimethylamino-2-nitroethylene, TFA, 0 ºC then r.t. (b) LAH, THF,
-78 ºC then r.t.
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Scheme 8 shows that after obtaining the formamide 29 with a refluxing mixture of
ethyl formate in methanol (90% yield), phosphoryl chloride was employed to cyclize ring
B to give the imine 30 via Bischler-Naperalski reaction90,91,92 . Without isolating the
dihydro-β-carboline 30, the fourth ring in 31 was constructed by using methylvinyl
ketone and zinc chloride in methanol at reflux temperature (64% yield)93. HornerWadsworth-Emmons reaction, i.e. replacement of ketone with olefinic methyl ester 32,
was accomplished by using trimethyl phosphonoacetate and sodium hydride in THF,
yielding 98%94,95. The reduced compound 33 was obtained by simply employing
hydrogen and palladium as catalyst with 55% yield.

Scheme 8. (a) ethyl formate, MeOH, reflux (b) POCl3, 50 ºC (c) methylvinyl ketone,
ZnCl2, methanol, relux (d) trimethyl phosphonoacetate, NaH, THF, 0 ºC than r.t. (e) H2,
Pd/C, MeOH.
Wolff-Kishner reduction of ketone 31 was first carried out with hydrazine sulfate
and potassium hydroxide in ethylene glycol at 190 ºC without success96. Only after
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substituting hydrazine hydrate for hydrazine sulfate, it was possible to obtain 34 with
86% yield as depicted in Scheme 9.

Scheme 9. NH2NH2.H2O, KOH, ethylene glycol, 190 ºC.
The final three steps to obtain the tetrahydro-β-carboline 37 are shown in Scheme
10. As described previously in relation with phenylpiperidines, formyl group introduction
alpha to the methyl ester 33 was carried out with lithium diisopropylamide and methyl
formate in THF; however the yield was significantly low when compared to 21 (10%).
After obtaining 35 as a mixture of tautomers, the next step was to form the acetal moiety
with timethyl orthoformate and tosic acid in refluxing methanol, which gave 36 with 69%
yield82. Elimination of one acetal methoxyl group using a strong base, potassium tertbutoxide, in dimethylformamide gave the methoxyvinyl moiety in 37 with 31% yield. As
discussed earlier, it is expected that the (E)-isomer was obtained83 due to higher repulsion
energy of oxygen atoms while in (Z)-configuration.
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Scheme 10. (a) LDA, methyl formate, THF, -78 ºC then r.t. (b) trimethylorthoformate,
PTSA, MeOH (c) t-BuOK, DMF, 60 ºC
Oxidation at 7-position of 33 was carried out by [bis-(trifluoroacetoxy)-iodo]benzene (PIFA) as the oxidizer in a mixture of acetonitrile and water at 0 ºC under
argon97 (Scheme 11). The presence of the oxidized compound was confirmed by mass
spectroscopy and proton NMR, that is, the absence of indolic proton and the appearance
of a signal upfield in the

13

C spectrum (C2). The reaction was performed four times

under similar conditions; however after six attempts to purify 38 by silica gel column
using different mobile phases, the compound could not be isolated with sufficient purity
for testing. Only after using preparative HPLC to isolate 38, it was possible to obtain it
with reasonable purity according to analytical HPLC (94.3%) at 15% yield.
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Scheme 11. PIFA, MeCN, H2O.
8.3 Sterereochemistry considerations
Previously, the focus on the discussion was based on the synthetic strategies and
the problems encountered as well as how to circumvent them. Notwithstanding, besides
mentioning which methoxyacrylate geometric isomer was obtained, nothing was said
about the absolute configuration of the different stereogenic centers observed during the
course of these syntheses, especially regarding the final products submitted for biological
evaluation. Synthesis of piperidines 6 and 15 were carried out by reductive amination
between m-anisidine and 1-benzyl-3-piperidone employing the non-stereoselective
reducing agent NaBH(OAc)3, therefore it is expected that they were obtained as racemic
mixtures. On the other hand, synthesis of tetrahydro-β-carbolines generated up to three
chiral centers, thus they deserve a more detailed discussion.
Compound 31 and its derivative 34 have one chiral center (see position 3 in
Figure 21) and they were first analyzed by analytical HPLC using a chiral column with
cellulose tris-(4-methoxybenzoate) coated on silica gel. Moreover, the chromatograms
showed two distinct peaks, which says that they were obtained as a mixture of
enantiomers. Moreover, the specific rotation for 31 was zero, proving that both
compounds were obtained as racemic mixtures. In regard to compound 33, more
extended considerations are necessary since it has two stereocenters (see positions 3 and
15 in Figure 21). As in the case of compounds 31 and 34, it was observed that the chiral
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separation of 33 showed two peaks and the specific rotation was zero, which means that
this compound was obtained as a racemic mixture. Fact also confirmed by the single TLC
spot isolated during the course of the synthesis.

Figure 21 - Compound 33 ring numbering.

As it is displayed in Figure 22, there are four diastereoisomers that could be
obtained. Since the optical rotation of the tested substance was zero, they must be a pair
of either 3S, 15R and 3R, 15S or 3S, 15S and 3R, 15R isomers. The question that remains
is what pair of enantiomers were submitted to biological testing. In order to answer this
question, different NMR techniques were performed, namely DEPT135, COSY, HMQC
and NOESY as well as the commonly used proton and carbon ones. After carefully
analyzing these spectra, it was possible to draw some conclusions about which pair of
enantiomers was produced. Following chemical shifts assignments of each carbon and the
hydrogens connected to these carbons, NOESY spectrum showed a correlation between
the indolic proton at 1-position and the proton attached to carbon 15, which means that
the distance separating these protons must be less than 5 Å in order to this correlation to
be observed. By employing molecular mechanics energy minimization (MM2;
ChemBioDraw 12.0), it was visible that the only pair of enantiomers that fulfilled the less
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than 5 Å requirement was 3S, 15R and 3R, 15S isomers, as opposed to the other pair (3S,
15S and 3R, 15R), which showed distances greater than 5 Angstroms.

Figure 22 - Four diastereomers of compound 33 and the distances between position 1 and
position 15.
Indeed, not only NMR techniques, but also the crystal structure, obtained by
solubilizing the hydrochloride salt of compound 37 (a derivative of 33) in ethanol and
then evaporate the solvent, corroborates the conclusion about which pair of enantiomers
underwent biological evaluation. Although only one isomer was crystallized, it is evident
in Figure 23 that the recovered crystal was the 3S, 15R isomer of 33, which belongs to the
same pair examined before by NMR techniques. Interestingly, the crystal structure also
confirmed that the methoxyacrylate geometric isomer (37) acquired was, as discussed
above, the trans-compound. Moreover, despite the fact that no crystal structure of 7 was
analyzed, it is possible, taking into account the energy minimization differences between
cis and trans isomers as previously considered, to infer that the isomer produced was the
trans compound.
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Figure 23 - X-ray crystal structure of compound 37. Carbons in gray, nitrogens in blue
and oxygens in red.
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9. Biological results and discussion
Initially, compounds in table 2 were pre-screened to compare their percentage of
binding with the reference compound, the opioid receptor antagonist naloxone, for each
human opioid receptor. The constant of inhibition (Ki) and the half maximum inhibitory
concentration (IC50) where further evaluated for compounds that displayed a percentage
greater than 50%, as highlighted in table 2. Most of compounds were tested as either
hydrochloride salt (HCL) or monobasic oxalate salt (OXA); the remaining substances
were evaluated as free bases.
Table 2- Percentage of binding compared to the reference compounds. OXA: monobasic
oxalate salt; HCL: hydrochloride salt.
Compound
μ % binding
δ % binding
κ % binding
Mitragynine

88.16

75.52

90.21

2.22

-16.97

1.48

MA66 OXA

3.73

MA71 OXA
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0.47

52.23

15.72

-8.32

31.03

29.58

-7.66

51.35

80.93

87.80

25.95

72.59

58.30

10.79

-7.59
-7.51 (HCL)

46.81
42.01 (HCL)

5.14
7.79 (HCL)

MA92 OXA

MA94 OXA

MA114

MA127

MA103
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14.55

8.33

8.64

0.78

-16.64

90.84

14.86

11.56

75.58

2.43

48.82

26.48

MA104 HCL

MA91 OXA

MA108 HCL

MA116
From the preliminary qualitative binding assays depicted above, two compounds
had significant displacement on human μ-receptors, two on δ-receptors and four on κreceptors. Phenylaminopiperdine 15 and phenylpiperidine 20 lack binding affinity,
however the flexible phenylamidopiperdine 6 as well as phenylpiperidines 7, 24 and 25
had noticeable displacement on at least one type of opioid receptor. One explanation for 6
having κ-opioid affinity, when compared to 15, is that it possesses a propyl group in the
anilinic nitrogen, as it is also the case in fentanyl, which has κ- and μ-opioid affinity. The
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methoxyvinyl group alpha to the methyl ester in 7 is important for the affinity for μ- and
δ-receptors, since a similar compound 20 does not have affinity for any receptor.
Selectivity change from κ-receptor to μ- and δ-receptors was observed by transforming
the tertiary hydroxyl group in the piperidine ring of 24 into the acetoxy moiety in 25. In
the case of the more rigid tetrahydro-β-carbolines, only two out of five substances had
considerable displacement on κ-receptors. The methyl ester in 33 and 37 seems to be
important for κ-receptor affinity, since the tetrahydro-β-carbolines 31 and 34 did not
show significant displacement. Surprisingly, compound 38, which is similar to the
efficacious antinociceptive agent 7-hydroxymitragynine (about 10 times the relative
potency of morphine), did not display substantial displacement of naloxone in any
receptor type.
Compounds that had a percentage of displacement greater than 50% in relation to
naloxone were further incubated with radioligands specific for each opioid receptor:
[3H]DAMGO (µ), [3H]Enkephlin (δ) and [3H]U-69,593 (κ). Unfortunately, none of the
compounds synthesized showed binding affinity as low as mitragynine (determined by
our group), as displayed in table 3. With the exception of compounds 33 and 37, all
compounds showed values in the micromolar range. The compound with the highest
binding affinity was the tetrahydro-β-carboline 33, with a Ki value of 391.4 nM for κreceptor. Introduction of a methoxyvinyl moiety alpha to the methyl ester in 33 afforded
37, which caused an almost two-fold decrease in affinity for κ-receptor. On the other
hand, installation of the same moiety in the flexible phenylpiperidine 20, which did not
show significant naloxone displacement, provided 7, with a binding affinity for μ- and δreceptors of 2.097 μM and 8.836 μM, respectively. Neither the methoxyvinyl in 7, nor the
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acetoxy group in 25 had impact on μ affinity, nevertheless the binding affinity of 25 for
the δ-receptor diminished by a factor of four. When comparing κ-receptor affinities,
tetrahydro-β-carbolines revealed higher binding affinity than piperidines. Conversely,
some piperidines displayed μ- and δ-receptors affinity, but no tetrahydro-β-carboline
demonstrated significant affinity for those receptors.
It is also worth bringing into attention the absolute configuration of the
compounds tested. Out of the two piperidine derivatives with a stereocenter, the one that
had considerable inhibition, compound 6, was obtained in a racemic fashion.
Unfortunately, nothing can be said about which isomer is the major responsible for the
activity, since they were not evaluated independently. On the other hand, the more
complex tetrahydro-β-carbolines, have up to three stereocenters. As none of the
tetrahydro-β-carbolines, 33 and 37, had significant displacement in μ- and δ-receptors
compared to mitragynine, it is possible to say that not only the ethyl group at position 20
in mitragynine (Figure 13) may play an role in the activity on these receptors, but also the
absolute configuration of the pair of enantiomers tested. Indeed, though one compound
shows identical configuration as mitragynine (see 3S,15R in Figure 22), the other displays
the opposite on both positions. The same can be said about the Ki values of 33 and 37 on
κ-receptors, which were not as low as for mitragynine. Interestingly, the mixture of
enantiomers 33 reveals a two-fold decrease in affinity on κ-receptors when compared to
mitragynine, which can be explained by the fact that 50% of the composition is
composed by the 3R,15S isomer. In fact, the natural product speciociliantine also has the
opposite configuration on position 3 and it has an 13-fold decreased affinity when
confronted with mitragynine. Finally, the reason why compound 38, which was based on
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the efficacious antinociceptive substance 7-hydroxymitragynine, did not show significant
naloxone displacement is that it was evaluated as a mixture of enantiomers. It can also be
added that the hydroxyl group configuration at the 7-position, which in 7hydroxymitragynine is α, was not determined in 38, thus there may be a chance that this
is another justification for why this compound was not significantly active.
Figures 24 through 27 show the binding curves as well as Ki and IC50 values of
compounds that showed significant displacement.
Table 3 - Inhibition constant values for each receptor type. N.D.: Not determined
μ [3H]DAMGO
Ki (μM)

δ [3H]Enkephlin
Ki (μM)

κ [3H]U-69,593
Ki (μM)

0.0820 ± 0.0055

0.3828 ± 0.0580

0.2156 ± 0.0149

6
(MA71 OXA)

N.D.

N.D.

1.885 ± 0.209

7
(MA114)

2.097 ± 0.190

8.836 ± 1.127

N.D.

24
(MA94 OXA)

N.D.

N.D.

8.347 ± 2.607

25
(MA127)

1.982 ± 0.327

38.92 ± 9.19

N.D.

33
(MA91 OXA)

N.D.

N.D.

0.3914 ± 0.0300

37
(MA108 HCL)

N.D.

N.D.

0.7257 ± 0.1548

Compound
Mitragynine
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Figure 24 - Binding curves for compound 7 (μ- and δ-receptors).

Figure 25 - Binding curves for compound 25 (μ- and δ-receptors).
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Figure 26 - Binding curves for compound 6 (MA71 OXA) and 24 (MA94 OXA)
(κ-receptor).

Figure 27 - Binding curves for compounds 33 (MA91 OXA) and 37 (MES147 HCL;
obtained by the same method employed for MA108 HCL) (κ-receptor).
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10. Final considerations
The biological results discussed above clearly show that piperidines
(phenylpiperidines, phenylaminopiperidines and phenylamidopiperidines) displayed
binding affinities that are lower than tetrahydro-β-carbolines affinities. Moreover, none of
the compounds synthesized exhibited binding affinities lower than mitragynine.
However, those binding studies demonstrated that these compounds showed moderate
selectivity among μ-, δ- and κ-opioid receptors. Although piperidines had affinities in the
micromolar range, two of them had significant inhibition constant on κ-receptors, but no
expressive inhibition on μ- and δ-receptors was observed. Conversely, the other two
piperidines with significant affinity for μ- and δ-receptors did not show important affinity
for κ-receptors. In the case of tetrahydro-β-carbolines, they revealed higher binding
affinities for κ-receptors than the piperidines. A general conclusion that can be drawn is
that the higher flexibility of the piperidines and less similarity to mitragynine are
detrimental to the overall binding affinity for opioid receptors. Indeed, tetrahydro-βcarbolines, which are structurally closer to mitragynine, showed affinities in the
nanomolar range for at least one opioid receptor. It is also worth pointing out that the
synthetic methods used to obtain these compounds did not take into consideration the
stereoisomers produced during the synthesis. This drawback was more evident in the case
of tetrahydro-β-carbolines synthesis, which generated multiple diastereoisomers.
Isolation of these stereoisomers by preparative chiral chromatography, for instance, could
have provided more insights about the requirements for opioid receptor binding.
As it was said before, the flexibility related to piperidines did not produce any
significant affinity towards any opioid receptors when compared to mitragynine, since
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molecules with more degrees of freedom are supposed to have less affinity. Indeed, the
structurally rigid four-ringered terahydro-β-carbolines had the highest affinity on at least
one type of opioid receptors, namely κ-receptors. Although no functional tests were
performed, the higher affinity on κ-opioid receptors when compared to the other two
receptor types may be advantageous in the future, as κ-receptors agonists are linked to the
suppression of the rewarding effects induced by morphine98.
Regarding the tetrahydro-β-carbolines biologically tested, it is worth noting that
some portions of the four-ringered molecule play an important part on κ-opioid affinity,
that is the methyl ester and the methyl methoxyacrylate moiety. While the methoxy allyl
group is detrimental to affinity, the methyl ester at C15 revealed κ-affinity very close to
mitragynine. In fact, unsubstituted and ketone substituted compounds at 15-position did
not show any significant affinity for κ-receptors. From these observations, it is plausible
to say that some portions of the designed compounds might not be necessary for affinity.
Therefore, it is possible to address that the indolic portion is not essential, whereas the
double-ringed heterocycle, octahydro-1H-quinolizine is the common feature between the
active and not active tetrahydro-β-carbolines. Moreover, this multi-substituted moiety
(mainly phenyl and methyl substitutions) is present in recent studies that show opioid
affinity99. Consequently, octahydro-1H-quinolizine derivatives might be worthwhile to
investigate in the future for opioid affinity. Furthermore, this work demonstrated that
variations at the 15-position change opioid affinities dramatically, hence different groups
at this position could be also explored for general opioid affinity.
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11. Experimental section
Chromatography was performed with silica gel 60 (230 x 400 mesh). Mass
spectra were obtained on a Waters micromass ZQ detector. NMR spectra were recorded
on either a Bruker AVIII 400 spectrometer or Bruker DRX500. HPLC analyses were
performed on a reverse phase XTerra R8 (5 m) column (4.6 X 100 mm) with 30% water,
10% NH4OH solution in H2O and 60% of CH3CN as the mobile phase for 5 minutes, then
the gradient changed to 100% CH3CN in 5 minutes and the column was washed with
CH3CN for another 5 minutes. The flow rate was maintained at 1 mL/min on a Waters
apparatus (Photodiode Array detector 996 and Separation Module 2695). Peaks were
monitored at maximum absorbance from 210 to 400 nm. Chiral separations were
performed on the same Waters apparatus with a Daicel Chemical Industries Chiracel OJH column (250 X 4.6 mm) using isopropanol with 0.5% diethylamine and hexane as
eluents. Initial condition was 23% of isopropanol for 5 minutes at 1.45 mL/min, then a
gradient to 10% isopropanol from 5 to 10 minutes, and finally maintaining 10% for the
rest of chromatography analysis. Optical rotations were measured with Rudolph Research
Analytical Autopol IV at 589 nm and concentration of 10% (m/v) in chloroform.
1-benzyl-N-(3-methoxyphenyl)piperidin-3-amine (13; MA62): 5.006 g (22.18 mmol)
of 1-benzyl-3-piperidone hydrochloride was dissolved in water, basified with K2CO3,
extracted three times with ethyl acetate and washed with brine. The organic phase was
dried over MgSO4 and the solvent was evaporated using reduced pressure, giving 4.0520
g (21.42 mmol) of an oily product (97% yield). In a round-bottom flask was added 75
mL of 1,2-dichloroethane, 2.51 mL (21.42 mmol) of m-anisidine and 4.0520 g (21.42
mmol) of 1-benzyl-3-piperidone. To the stirring solution under argon atmosphere was
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added 1.22 mL (21.42 mmol) of acetic acid and 6.651 g (31.49 mmol) of NaBH(OAc)3.
The reaction mixture was stirred for 72 h at room temperature and then quenched with
1N NaOH, extracted with three portions of DCM, dried over MgSO4, filtered and the
solvent was evaporated under reduced pressure. The crude extract was purified by a silica
column using a gradient of ethyl acetate/hexanes (from 10% to 70% ethyl acetate). It was
obtained 3.17 g (10.7 mmol) of a yellowish oily liquid (50% yield). MS (ESI) m/z 296 (M
+ 1).
1

H NMR (400MHz, CDCl3): δ ppm 7.36 (d, J = 4.5 Hz, 4H ,Ar), δ 7.29 (dd, J = 8.5, 4.2,

1H, Ar), δ 7.09 (t, 1H, J = 8 Hz, Ar), δ 6.28 – 6.24 (m, 2H, Ar), δ 6.19 (t, 1H, J = 4 Hz,
Ar), δ 3.78 (s, 3H), δ 3.58 (s, 1H), δ 3.55 (d, 2H, J = 4 Hz), δ 2.76 (s, 1H), δ 2.43 (s, 2H),
δ 2.31 (s, 1H), δ 1.76 (m, 2H), δ 1.58 (m, 2H).
13

C NMR (101 MHz, CDCl3): δ ppm 160.94 (Cq), 148.53 (Cq), 138.32 (Cq), 129.01

(CHar), 128.25 (2 CHar), 128.24 (2 CHar), 127.04 (CHar), 106.38 (CHar), 102.17,
99.04, 63.19 (CH2), 59.07 (CH2), 55.08, 53.70, 48.78, 47.70, 22.73 (CH2).
N-(3-methoxyphenyl)piperidin-3-amine (14; MA64): In a flask designed for a Parr
apparatus, approximately 150 mL of methanol was added along with 2.76 g (9.3 mmol)
of 1-benzyl-N-(3-methoxyphenyl)piperidin-3-amine (13) and 690 mg of palladium on
carbon (10%). The mixture was submitted to hydrogen atmosphere at 55 psi for 4 hours
at room temperature and then the catalyst was filtered off with Celite in a fritted funnel
under vacuum and the solvent was evaporated. Purification was performed using flash
chromatography with a gradient of dichloromethane and methanol with ammonia (from
5% to 10% methanol). It was obtained a yellow oil with 85% yield (1.83 g; 7.9 mmol).
MS (ESI) m/z 207.2 (M + 1).
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1

H NMR (400 MHz, CDCl3): δ ppm 7.06 (t, J = 8.1, 1H), 6.24 (dt, J = 8.0, 1.9, 2H), 6.18

(t, J = 2.2, 1H), 3.76 (s, 3H), 3.45 (s, 2H), 3.22 (d, J = 11.7, 1H), 2.88 – 2.91 (m, 1H),
2.71 (d, J = 8.5, 1H), 2.55 (dd, J = 11.7, 7.6, 1H), 2.48 (s, 1H), 1.93 (d, J = 11.7, 1H),
1.79 – 1.72 (m, 1H), 1.56 – 1.47 (m, 2H).
13

C NMR (101 MHz, CDCl3) δ 160.91, 148.43, 130.05, 106.27, 102.28, 99.09, 55.07,

51.91, 50.40(2C) 49.15(2C), 46.44, 30.57, 24.19.
methyl 5-(3-(3-methoxyphenylamino)piperidin-1-yl)pentanoate (15; MA66): To a
round-bottom flask equipped with a stirring bar, it was added 1.67 g (8.08 mmol) of N-(3methoxyphenyl)piperidin-3-amine (14) dissolved in 20 mL of DMF, 1.39 mL (1.89 g; 9.7
mmol) of methyl 5-bromovalerate and 3.34 g (24.2 mmol) of anhydrous potassium
carbonate. The mixture was stirred overnight at room temperature, poured in a sodium
carbonate solution (pH = 9), extracted with three 50 mL portions of ethyl acetate, washed
with three portions of brine, dried with Na2SO4, filtered and evaporated. The product was
isolated by flash chromatography starting with dichloromethane and then a gradient of
methanol/dichloromethane. It was obtained an yellow syrup with 53% yield (1.39 g; 4.33
mmol). MS (ESI) m/z 321.1 (M+ + 1).
1

H NMR (400 MHz, CDCl3) δ 7.05 (t, J = 8.1, 1H), 6.23 (d, J = 8.2, 2H), 6.17 (t, J = 2.2,

1H), 4.04 (s, 1H), 3.76 (s, 3H), 3.67 (s, 3H), 3.54 (s, 1H), 2.68 (s, 1H), 2.36 – 2.30 (m,
6H), 2.23 (s, 1H), 1.70 (d, J = 10.9, 2H), 1.64 (dd, J = 15.1, 7.6, 2H), 1.51 (tt, J = 9.0,
4.5, 4H).
13

C NMR (101 MHz, CDCl3) δ 174.00, 160.90, 148.49, 129.99, 106.26, 102.16, 99.98,

99.03, 59.19, 58.19, 55.02, 53.97, 51.46, 48.65, 33.87, 26.29, 22.90, 22.76.
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methyl

5-(3-(3-methoxyphenylamino)piperidin-1-yl)pentanoate

oxalate

(MA66

OXA):

A

methyl

5-(3-(3-

solution

of

72

mg

(0.225

mmol)

of

methoxyphenylamino)piperidin-1-yl)pentanoate in approximately 4 mL of THF was put
to stir at room temperature in a 20 mL vial when another solution of 62 mg (0.69 mmol)
oxalic acid in THF (approximately 4 mL) was added dropwise. It was observed that after
each drop a suspension was formed and soon disappeared into the yellowish solution. The
precipitate was visible only by addition of diethyl ether. The suspension was stirred for 1
h, filtered under reduced pressure in a fritted funnel, rinsed with approximately 180 mL
of ether and dried in high vacuum. A white powder was obtained with quantitative yield.
1

H NMR (400 MHz, DMSO) δ 6.96 (t, J = 7.9, 1H), 6.22 (d, J = 9.2, 2H), 6.13 (d, J =

8.3, 1H), 5.74 (br-s, 1H), 3.66 (s, 4H), 3.57 (s, 3H), 3.38 (d, J = 10.2, 1H), 3.29 (d, J =
8.4, 1H), 2.98 (t, J = 8.0, 2H), 2.78 (s, 1H), 2.49 (s, 2H), 2.33 (t, J = 7.0, 2H), 1.88 (s,
2H), 1.77 (d, J = 10.3, 1H), 1.63 (s, 2H), 1.53 – 1.49 (m, 2H), 1.40 (d, J = 10.3, 1H).
methyl

5-(3-(N-(3-methoxyphenyl)propionamido)piperidin-1-yl)pentanoate

(6;

MA71): methyl 5-(3-(3-methoxyphenylamino)piperidin-1-yl)pentanoate (15) (100 mg;
0.312 mmol) was dissolved in 4 mL of 1,2-dichloroethane (DCE) in a round-bottom flask
equipped with a condenser and stirring bar. To this solution, it was added 82 μL (0.936
mmol) of propionyl chloride and the mixture was refluxed for 3 hours. After this period
90 μL (0.65 mmol) of triethylamine in 1 mL of DCE was added dropwise over 5 minutes
and the reaction mixture was refluxed for another 2 hours. The mixture was poured into
K2CO3 solution and extracted with 3 portions of DCM, washed with brine, dried over
Na2SO4, filtered and evaporated. Purification took place by flash chromatography with
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silica gel and a gradient of methanol/DCM to give orange oil with 95% yield (111.4 mg;
0.296 mmol). MS (ESI) m/z 377.1 [M+ + H]. HRMS m/z 277.2433 (calculated 277.2440).
1

H NMR (400 MHz, CDCl3) δ 7.25 (t, J = 8.0, 1H), 6.87 (dd, J = 8.3, 2.1, 1H), 6.62 (d, J

= 7.7, 1H), 6.57 (s, 1H), 3.77 (s, 3H), 3.61 (s, 3H), 2.77 (d, J = 7.1, 1H), 2.32 - 2.22 (m,
5H), 1.90 (dd, J = 14.5, 7.1, 2H), 1.76 (t, J = 10.4, 2H), 1.59 – 1.56 (m, 2H), 1.57 (dd, J =
14.9, 7.4, 3H), 1.47 (dd, J = 15.1, 8.0, 2H), 1.06 (t, J = 7.5, 2H), 0.96 (t, J = 7.4, 3H).
13

C NMR (101 MHz, CDCl3) δ 173.83, 173.35, 160.15, 140.68, 129.76, 122.26, 116.17,

113.30, 57.75, 56.92, 55.34, 52.84, 51.82, 51.29, 33.74, 29.07, 28.26, 26.04, 24.30, 22.81,
9.48.
methyl 5-(3-(N-(3-methoxyphenyl)propionamido)piperidin-1-yl)pentanoate oxalate
(MA71

OXA):

methyl

5-(3-(N-(3-methoxyphenyl)propionamido)piperidin-1-

yl)pentanoate was dissolved in 2 mL of THF and put to stir in a 20 mL vial. Oxalic acid
(100 mg) dissolved in 2 mL of THF was added, but no precipitate was observed. A
suspension was only formed after adding few milliliters of anhydrous diethyl ether. The
precipitate was filtered with a fritted funnel under reduced pressure and the excess of
oxalic acid was rinsed with 200 mL of ether. A white solid was obtained (50.4 mg).
(Yield not calculated).
1

H NMR (400 MHz, DMSO) δ 7.37 (s, 1H), 7.01 (s, 1H), 6.83 (s, 2H), 4.71 (s, 1H), 3.77

(s, 3H), 3.58 (s, 3H), 3.46 (s, 1H), 3.37 (s, 1H), 3.21 (s, 1H), 2.88 (s, 2H), 2.49 (s, 3H),
2.34 (s, 2H), 1.83 (d, J = 25.9, 4H), 1.56 (d, J = 26.1, 4H), 1.08 (s, 2H), 0.88 (s, 3H).
1-benzyl-4-(2-methoxyphenyl)piperidin-4-ol (17; MA109): To an oven-dried 250 mL
two-neck round-bottom flask equipped with a condenser was added 989 mg (40.7 mmol)
of magnesium turnings, 50 mL of freshly dried THF, two crystals of iodine and
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approximately 5 mL of 1-bromo-2-methoxybenzene dissolved in 125 mL of THF. Using
a heat gun and vigorous agitation, the solution was heated until it became colorless. The
remaining solution of 1-bromo-2-methoxybenzene was added and the mixture was
refluxed for 2.5 hours and brought to room temperature. It was observed that the solution
turned into dark green over time and the magnesium disappeared after only one hour. In a
500 mL round-bottom flask, 6.60 mL (37.0 mmol) of N-benzyl-4-piperidone was
dissolved in 125 mL of THF at 0 °C. The Grignard reagent was then slowly transferred to
the piperidone solution and stirred for two hours. A solution of ammonium chloride was
added and the crude obtained by extracting with ethyl acetate, washing with brine, drying
with anhydrous sodium sulfate and concentrating. After purification using a
methanol/dichloromethane gradient in silica, it was obtained 2.97 g (10 mmol; 27%
yield). MS (ESI) m/z 298.3 [M+].
1

H NMR (400 MHz, CDCl3) δ 7.42 – 7.29 (m, 7H), 6.99 (td, J = 7.6, 1.0, 1H), 6.95 (d, J

= 8.2, 1H), 4.06 (s, 1H, OH), 3.89 (s, 3H), 3.63 (s, 2H), 2.81 (d, J = 10.8, 2H), 2.65 (td, J
= 11.8, 2.6, 2H), 2.17 (td, J = 12.8, 4.3, 2H), 2.07 (dd, J = 13.9, 2.5, 2H).
13

C NMR (101 MHz, CDCl3) δ 157.35, 138.71, 135.24, 129.34, 128.24, 126.98, 125.66,

121.19, 111.42, 71.15,63.38, 63.34, 63.30, 55.36, 55.32, 55.27, 55.23, 55.27, 49.30,
36.25.
1-benzyl-4-(2-methoxyphenyl)-1,2,3,6-tetrahydropyridine (18; MA110): Dehydration
of the tertiary alcohol took place by refluxing 40 mL of toluene with 2.97 g (10 mmol) of
1-benzyl-4-(2-methoxyphenyl)piperidin-4-ol (17) and 2.28 g (12 mmol) of ptoluenesulfonic acid for 27h. The mixture was poured into a potassium carbonate
solution, extracted with three portions (60 mL) of ethyl acetate and dried over sodium
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sulfate. After purification with methanol/dichloromethane in silica gel, 1.67 g (5.6 mmol)
of yellowish viscous oil with 56% yield was obtained. MS (ESI) m/z 280.3 [M+].
1

H NMR (400 MHz, CDCl3) δ 7.45 (d, J = 7.6, 2H), 7.39 (d, J = 7.1, 2H), 7.34 – 7.28 (m,

1H), 7.26 – 7.22 (m, 2H), 6.96 (t, J = 7.4, 1H), 6.90 (d, J = 8.1, 1H), 5.84 (s, 1H), 3.84 (s,
3H), 3.70 (s, 2H), 3.22 (s, 2H), 2.74 (t, J = 5.6, 2H), 2.61 (s, 2H).
13

C NMR (101 MHz, CDCl3) δ 156.85, 138.31, 129.45, 129.31, 129.27, 128.45,

128.23,128.13, 127.06, 120.56, 111.13, 110.83, 110.79, 84.72, 62.84, 55.36, 53.27, 49.94,
29.52.
4-(2-methoxyphenyl)-piperidine (19; MA111): To a hydrogenation flask with 130 mL
of ethanol was added 1.48 g (5.3 mmol) of 1-benzyl-4-(2-methoxyphenyl)-1,2,3,6tetrahydropyridine (18) and 300 mg of 10% w/w of palladium on carbon. The mixture
was shaken in a Parr hydrogenation apparatus under 55 psi of hydrogen for 47 hours.
Palladium and carbon were filtered off using Celite under reduced pressure. After
purification by chromatography with methanol with ammonia/dichloromethane, it was
obtained 726 mg (3.8 mmol) of a pale yellow solid with 72% yield. MS (ESI) m/z 192.3
[M+].
1

H NMR (400 MHz, CDCl3) δ 7.19 (dd, J = 13.3, 7.0, 2H), 6.94 (t, J = 7.4, 1H), 6.86 (d,

J = 8.0, 1H), 3.83 (s, 3H), 3.22 (d, J = 11.3, 2H), 3.13 – 3.07 (m, 2H), 2.80 (t, J = 11.6,
2H), 1.82 (d, J = 12.1, 2H), 1.66 (qd, J = 12.1, 3.1, 2H).
13

C NMR (101 MHz, CDCl3) δ 156.70, 134.52, 126.88, 126.62, 120.65, 110.35, 55.31,

47.04 (2C), 35.35, 32.73 (2C).
Methyl 5-(4-(2-methoxyphenyl)piperidin-1-yl)pentanoate (20; MA112): To 10 mL of
N,N-dimethylformamide was added 716 mg (3.74 mmol) 4-(2-methoxyphenyl)-
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piperidine (19) and 943 mg (11.2 mmol) of anhydrous sodium bicarbonate along with
0.591 mL (4.12 mmol) of methyl 5-bromovalerate. The mixture was stirred for two hours
at 60 °C. It was then extracted with ethyl acetated in aqueous potassium carbonate
(pH=9), washed with brine and dried over sodium sulfate. After flash column
chromatography using methanol/dichloromethane as eluents, 81.6% (930 mg; 3.05 mmol)
yield was obtained. MS (ESI) m/z 306.3 [M + 1].
1

H NMR (400 MHz, CDCl3) δ 7.21 (dd, J = 7.6, 1.5, 1H), 7.16 (td, J = 7.7, 1.5, 1H), 6.92

(t, J = 7.4, 1H), 6.84 (d, J = 8.2, 1H), 3.81 (s, 3H), 3.66 (s, 3H), 3.04 (d, J = 11.5, 2H),
2.99 - 2.92 (m, 1H), 2.41 -2.33 (m, 4H), 2.08 (td, J = 11.2, 3.7, 2H), 1.79 (dd, J = 9.8,
3.5, 3H), 1.75 - 1.70 (m, 1H), 1.68 – 1.54 (m, 4H).
13

C NMR (101 MHz, CDCl3) δ 174.01, 156.81, 134.36, 126.81, 126.56, 120.63, 110.28,

58.62, 55.31, 55.28, 54.58, 51.47, 51.45, 35.07, 33.95, 31.99, 26.50, 23.10.
Methyl 2-formyl-5-(4-(2-methoxyphenyl)piperidin-1-yl)pentanoate (21; MA113): It
was added 911 mg (2.98 mmol) of methyl 5-(4-(2-methoxyphenyl)piperidin-1yl)pentanoate (20) to an oven dried three-neck round-bottom flask with 40 mL of freshly
distilled THF in argon atmosphere. While maintaining the solution stirring at -70 °C, 3.7
mL (7.4 mmol) of lithium diisopropylamide in a 2 M solution was added dropwise. After
40 minutes, 0.922 mL (14.9 mmol) of methyl formate was added and the mixture was
agitated for one hour at -70 °C and for two hours at room temperature. The reaction
mixture was poured into a solution of ammonium chloride, extracted with ethyl acetate
and

dried

over

Na2SO4.

Purification

with

flash

chromatography

using

methanol/dichloromethane afforded 694 mg (2.08 mmol; 70%) of an orange sticky syrup.
MS (ESI-) m/z 332.3 [M -1].
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1

H NMR (400 MHz, CDCl3) δ 11.68 (s, 1H), 7.99 (s, 1H), 7.19 (dd, J = 12.9, 7.4, 2H),

6.92 (t, J = 7.5, 1H), 6.85 (d, J = 8.1, 1H), 3.82 (s, 3H), 3.67 (s, 3H), 3.14 (d, J = 11.7,
2H), 3.09 – 3.01 (m, 1H), 2.46 (t, J = 6.2, 2H), 2.40 – 2.37 (m, 2H), 2.28 – 2.21 (m, 2H),
1.93 – 1.89 (m, 4H), 1.76 (dt, J = 12.5, 6.3, 2H).
13

C NMR (101 MHz, CDCl3) δ 169.94, 156.70, 132.90, 127.27, 126.55, 120.77, 110.32,

55.26, 54.30, 53.77, 53.19, 51.52, 50.76, 34.66, 30.47, 23.70, 19.64.
(E)-methyl 2-(methoxymethylene)-5-(4-(2-methoxyphenyl)piperidin-1-yl)pentanoate
(7; MA114): In 125 mL of methanol in a round-bottom flask with a condenser was
dissolved 668 mg (2.0 mmol) of methyl 2-formyl-5-(4-(2-methoxyphenyl)piperidin-1yl)pentanoate (21) and added a total of 6.54 mL (30 mmol) of trimethyl orhoformate and
2.28 g (12.0 mmol) of p-toluenesulfonic acid. The mixture was refluxed for 12 hours and
extracted with three portions of ethyl acetate in aqueous K2CO3, washed with brine, dried
with Na2SO4, filtered and evaporated. After purifying three times with flash
chromatography employing methanol/dichloromethane as eluents, 114 mg (0.33 mmol;
16.5%) of pale yellow solid was obtained. MS (ESI+) m/z 348.3 [M + H]. HPLC analysis
showed 98% purity.
1

H NMR (400 MHz, CDCl3) δ 7.29 (s, 1H), 7.22 (dd, J = 7.5, 1.5, 1H), 7.23 – 7.14 (m,

1H), 6.92 (t, J = 7.5, 1H), 6.85 (d, J = 8.2, 1H), 3.81 (s, 3H), 3.80 (s, 3H), 3.70 (s, 3H),
3.05 (d, J = 11.5, 2H), 2.98 – 2.91 (m, 1H), 2.40 – 2.36 (m, 2H), 2.26 (t, J = 7.2, 2H),
2.11 – 2.04 (m, 2H), 1.80 – 1.75 (m, 4H), 1.70 – 1.62 (m, 2H).
13

C NMR (101 MHz, CDCl3) δ 168.88, 158.89, 156.80, 134.51, 126.75, 126.58, 120.62,

110.66, 110.27, 61.20, 58.75, 55.31, 54.51, 51.13, 35.09, 32.06, 26.03, 21.99.
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(E)-methyl 2-(methoxymethylene)-5-(4-(2-methoxyphenyl)piperidin-1-yl)pentanoate
hydrochloride

(MA114

HCL):

(E)-methyl

2-(methoxymethylene)-5-(4-(2-

methoxyphenyl)piperidin-1-yl)pentanoate (73.7mg; 0.212 mmol) was dissolved in THF
and a saturated solution of hydrochloric acid in diethyl ether as added. After stirring for
few minutes, the solvent was evaporated under reduced pressure and 57 mg (0.14 mmol)
a pale yellow solid was obtained by drying in high vacuum.
1

H NMR (400 MHz, DMSO) δ 10.34 (s, 1H), 7.20 (t, J = 7.7, 1H), 7.11 (d, J = 7.1, 1H),

6.97 (d, J = 8.2, 1H), 6.92 (t, J = 7.4, 1H), 3.77 (s, 3H), 3.73 – 3.66 (m, 2H), 3.62 – 3.59
(m, 1H), 3.48 (d, J = 9.7, 2H), 3.37 (s, 6H), 3.27 – 3.13 (m, 2H), 3.02 (s, 3H), 2.01 (d, J =
11.5, 2H), 1.85 (d, J = 13.7, 2H), 1.74 (d, J = 5.6, 2H).
4-(2-methoxyphenyl)-4-hydroxypiperidine (23; MA118): In a pressure flask for a Parr
hydrogenation

apparatus

was

added

1.40

g

(4.7

mmol)

of

1-benzyl-4-(2-

methoxyphenyl)piperidin-4-ol (17) dissolved in 100 mL of ethanol. Palladium on carbon
(700 mg; 10%) was slowly added to the solution and the flask was shaken for 15 hours
under 55 psi of hydrogen at room temperature. The palladium and carbon were filtered
off under reduced pressure using Celite as a filter aid. The product was purified by
column chromatography using a gradient of methanol/dichloromethane. A white solid
was obtained (747.7 mg; 3.61 mmol) with 76.8% yield. MS (ESI) m/z 208.2 [M + 1].
1

H NMR (400 MHz, DMSO) δ 7.53 (d, J = 7.6, 1H), 7.18 (t, J = 7.7, 1H), 6.95 (d, J =

8.2, 1H), 6.89 (t, J = 7.5, 1H), 4.55 (br s, 1H), 3.78 (s, 3H), 2.94 (t, J = 11.7, 3H), 2.69 (d,
J = 10.4, 2H), 2.28 (td, J = 12.8, 4.5, 2H), 1.35 (d, J = 12.6, 2H).
13

C NMR (101 MHz, DMSO) δ 171.84, 156.85, 137.69, 136.39, 128.12, 126.72, 120.59,

112.20, 71.27, 55.69, 42.28, 36.15.
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Methyl 5-(4-hydroxy-4-(2-methoxyphenyl)piperidin-1-yl)pentanoate (24; MA94): In
a 35 mL round-bottom flask was put a solution of 612.8 mg (2.95 mmol) of 4-(2methoxyphenyl)-4-hydroxypiperidine (23) in 7 mL N,N-dimethylformamide, 0.464 mL
(3.24 mmol) of methyl 5-bromovalerate and 734 mg (8.85 mmol) of sodium bicarbonate.
The reaction mixture was stirred at 60 °C and followed by TLC. After 1:15 h no starting
material could be observed. The product was poured in aqueous NaHCO3 and extracted
with three portions (35 mL) of ethyl acetate, washed three times with brine, dried over
Na2SO4, filtered and evaporated. Purification took place by using a silica gel column and
methanol/dichloromethane gradient (2 - 20% of methanol). A yellow oil was obtained
with 70% yield (664.9 mg; 2.07 mmol).
1

H NMR (400 MHz, CDCl3) δ 7.28 (dd, J = 7.8, 1.5, 1H), 7.26 – 7.22 (m, 1H), 6.96 (dd,

J = 7.6, 1.1, 1H), 6.92 (d, J = 7.4, 1H), 4.06 (s, 1H), 3.89 (s, 3H), 3.66 (s, 3H), 2.86 (d, J
= 11.3, 2H), 2.64 (t, J = 10.7, 2H), 2.50 (t, J = 7.3, 2H), 2.35 (t, J = 7.0, 2H), 2.20 (td, J =
13.5, 4.7, 2H), 2.05 (dd, J = 14.1, 2.6, 2H), 1.64 (m, 4H).
13

C NMR (101 MHz, CDCl3) δ 173.94, 157.20, 136.39, 134.57, 128.37, 125.59, 121.23,

111.34, 70.80, 58.13, 55.29, 51.50, 49.15, 35.72, 33.83, 26.08, 22.96.
methyl 5-(4-hydroxy-4-(2-methoxyphenyl)piperidin-1-yl)pentanoate oxalate (MA94
OXA) : A solution of approximately 180 mg (0.56 mmol) of methyl 5-(4-hydroxy-4-(2methoxyphenyl)piperidin-1-yl)pentanoate in THF was stirring when 178 mg (1.98 mmol)
of oxalic acid dissolved in 10 mL of diethyl ether was added. The suspension was stirred
for one hour and then filtered under reduced pressure and washed with 200 mL of ether to
remove the excess of oxalic acid. A white solid was obtained (244 mg; 0.59 mmol).
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1

H NMR (400 MHz, DMSO) δ 7.54 (d, J = 7.5, 1H), 7.24 (t, J = 7.1, 1H), 7.00 (d, J =

8.1, 1H), 6.95 (t, J = 7.0, 1H), 5.18 (s, 7H), 3.84 (s, 3H), 3.63 (s, 3H), 3.26 (d, J = 7.8,
4H), 3.03 (m, 2H), 2.70 (dd, J = 19.7, 11.3, 2H), 2.37 (t, J = 7.0, 2H), 1.76 (d, J = 11.0,
4H), 1.65 (m, 2H).
Methyl 5-(4-acetoxy-4-(2-methoxyphenyl)piperidin-1-yl)pentanoate (25; MA127): In
a 10 mL round-bottom flask dried with an heat gun was added 1.3 mL (18 mmol) of
dimethylsulfoxide and 1.6 mL of acetic anhydride (17 mmol). The solution was stirred
under argon atmosphere for 30 min. After this period, a solution of 249.5 mg (0.776
mmol) of methyl 5-(4-hydroxy-4-(2-methoxyphenyl)piperidin-1-yl)pentanoate (24) in 1.0
mL (14 mmol) of dimethylsulfoxide was added and the stirring mixture turn into yellow.
The reaction mixture was followed by TLC for 21 hours, but no progress was observed
after 5 hours. The solution turned into orange and it was extracted with an aqueous
solution of K2CO3 (pH=9) and three portions of 25 mL of ethyl acetate, dried over
anhydrous Na2SO4 and evaporated under reduced pressure. The product was purified by
flash chromatography using a gradient of MeOH (saturated with NH3)/DCM (2 – 4% of
MeOH). A yellow solid was obtained with a yield of 41.4% (116.5 mmol; 0.321 mmol).
MS (ESI+) m/z 264.2 [M + H]+. HPLC analysis showed 95.8% purity.
1

H NMR (400 MHz, CDCl3) δ 7.28 (d, J = 6.8, 1H), 7.25 – 7.21 (m, 1H), 6.93 (t, J = 7.6,

1H), 6.88 (d, J = 8.2, 1H), 3.81 (s, 3H), 3.67 (s, 3H), 2.87 (d, J = 11.4, 2H), 2.67 – 2.60
(m, 2H), 2.45 (dd, J = 15.0, 8.7, 3H), 2.37 (dd, J = 13.7, 6.8, 3H), 2.27 – 2.20 (m, 2H),
2.04 (s, 3H), 1.71 – 1.58 (m, 4H).
13

C NMR (101 MHz, CDCl3) δ 173.96, 169.42, 156.83, 136.39, 128.65, 126.72, 120.47,

111.61, 99.99, 79.87, 63.60, 58.10, 55.20, 51.51, 49.38, 33.81, 33.57, 26.19, 22.92, 21.71.
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(E)-4-methoxy-3-(2-nitrovinyl)-1H-indole (27; MA81): Trifluoroacetic acid (20 mL)
was poured into a round-bottom flask and brought to 0° C under agitation in argon
atmosphere when 4.34 g (37.4 mmol) of (E)-N,N-dimethyl-2-nitroethenamine was
introduced. To this solution, 5.00 g (34.0 mmol) of 4-methoxyindole was added and
stirred for 15 minutes. Since 4-methoxyindole did not dissolve, 20 mL of DCM was
added, bringing it to solution, which was stirred for another 30 minutes at room
temperature. The reaction mixture was poured into ice-water and extracted with three 120
mL portions of ethyl acetate. The organic phase was then put in a conical flask and a
saturated solution of NaHCO3 was slowly added under vigorous agitation until no CO2
formation was observed. The crude extract was washed with brine, dried over Na2SO4,
filtered and evaporated to obtain a dark orange solid (yield not calculated).
1

H NMR (400 MHz, DMSO) δ 12.23 (s, 1H), 8.56 (d, J = 13.3, 1H), 8.25 (s, 1H), 8.10 (d,

J = 13.3, 1H), 7.16 (t, J = 7.9, 1H), 7.10 (d, J = 8.0, 1H), 6.73 (d, J = 7.7, 1H), 3.95 (s,
3H).
13

C NMR (101 MHz, DMSO) δ 154.11, 139.26, 135.97, 132.71, 124.72, 115.60, 108.42,

106.44, 102.95, 99.99, 55.79.
4-methoxytryptamine (28; MA83): Freshly distilled THF (250 mL) was put in a roundbottom flask along with 7.41 g (34 mmol) of (E)-4-methoxy-3-(2-nitrovinyl)-1H-indole.
The solution was brought to -78° C with acetone/dry ice bath and stirred under argon
atmosphere for 20 minutes. After this period, 28.3 mL (68 mmol) of lithium aluminum
hydride in THF (2.4 M) was added dropwise over 20 minutes and agitated for another 30
minutes. The reaction mixture was brought to room temperature, stirred overnight and
quenched with 2.7 mL of water, 2.7 mL of aqueous NaOH (15%) and 2.7 mL of water
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until no hydrogen formation was observed. The precipitate was filtered off and rinsed
with ethyl acetate. The solvents were evaporated and the solid was dissolved in ethyl
acetate, dried over Na2SO4, filtered and evaporated. The compound was purified with a
silica gel column using a gradient of methanol (with dissolved NH3)/DCM. It was
obtained 1.0 g of an orange solid with an overall yield (2 steps) of 15.5 %. MS (ESI) m/z
191.1 [M+ + H].
1

H NMR (400 MHz, CDCl3) δ 8.63 (s, 1H), 7.07 (t, J = 7.9, 1H), 6.94 (d, J = 8.1, 1H),

6.84 (s, 1H), 6.47 (d, J = 7.7, 1H), 3.90 (s, 3H), 3.01 (s, 4H), 2.01 (s, 2H).
13

C NMR (101 MHz, CDCl3) δ 154.81, 138.30, 122.64, 121.21, 117.32, 113.73, 104.60,

99.25, 55.09, 43.10, 30.82.
N-(2-(4-methoxy-1H-indol-3-yl)ethyl)formamide (29; MA95): In a round-bottom flask
equipped with a condenser was added 5.03 g (26.4 mmol) of 4-methoxytryptamine (28),
30 mL of ethyl formate and 10 mL of methanol (4-methoxytryptamine is not soluble in
ethyl formate). The solution was refluxed for 20 hours and solvents evaporated. The
product was purified with flash chromatography using silica gel and 3% methanol/DCM
as eluent to obtain 5.20 g (24.0 mmol) with 90% yield.
1

H NMR (400 MHz, CDCl3) δ 8.59 (s, 1H), 8.04 (s, 1H), 7.10 (t, J = 8.0, 1H), 6.96 (dd, J

= 8.2, 3.1, 1H), 6.84 (d, J = 2.3, 1H), 6.51 (d, J = 7.8, 1H), 6.08 (s, 1H), 3.93 (d, J = 1.9,
3H), 3.62 (q, J = 6.2, 2H), 3.09 (t, J = 6.5, 2H).
13

C NMR (101 MHz, CDCl3) δ 161.49, 154.40, 138.29, 122.82, 121.55, 117.17, 112.79,

104.92, 99.44, 55.14, 39.81, 26.29.
5-methoxy-4,9-dihydro-3H-pyrido[3,4-b]indole (30; MA97): To a round-bottom flask
were added 4.1 g (18.8 mmol) of N-(2-(4-methoxy-1H-indol-3-yl)ethyl)formamide (29)
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and 25 mL of phosphorus oxychloride (26.9 mmol). The mixture was stirred at 50 °C for
1:20 h, POCl3 was partially evaporated under reduced pressure (15 minutes) and then
quenched with ice/water (caution: very reactive!). The dark green mixture was poured
into a conical flask and ammonium hydroxide was added under agitation, making the
color change to orange. The product was extracted with 4 portions of DCM, washed with
brine, dried over Na2SO4, filtered and evaporated.
1

H NMR (400 MHz, DMSO) δ 11.29 (s, 1H), 8.30 (s, 1H), 7.07 (t, J = 7.9, 1H), 6.97 (d, J

= 8.2, 1H), 6.47 (d, J = 7.7, 1H), 3.83 (s, 3H), 3.72 (t, J = 7.6, 2H), 2.92 (m, 2H).
13

C NMR (101 MHz, DMSO) δ 155.23, 151.72, 138.31, 127.71, 125.03, 114.03, 110.53,

105.94, 99.87, 55.52, 48.64, 20.97.
8-methoxy-1,3,4,6,7,12b-hexahydroindolo[2,3-a]quinolizin-2(12H)-one (31; MA103
[MA88]): To a round-bottom flask equipped with a condenser were added 2.36 g (11.8
mmol) of 5-methoxy-4,9-dihydro-3H-pyrido[3,4-b]indole (30) dissolved in 400 mL of
methanol, 236 mg (1.73 mmol) of zinc chloride and 2.9 mL (35.4 mmol)mg of
methylvinylketone. The mixture was refluxed under agitation for 4 hours and then the
solvent was evaporated. The crude material was basified with aqueous K2CO3, extracted
with ethyl acetate, dried over Na2SO4, filtered and evaporated. Product isolation was
carried out by flash chromatography in silica gel using a gradient of ethyl
acetate/hexanes. After evaporating the solvent, 2.73 g (10.1 mmol) of white powder was
obtained with a 64% yield. MS (ESI) m/z 271 (M + 1). HPLC purity 99%.
1

H NMR (400 MHz, CDCl3) δ 8.06 (s, 1H), 7.06 (t, J = 8.0, 1H), 6.93 (d, J = 8.1, 1H),

6.50 (d, J = 7.7, 1H), 3.90 (s, 3H), 3.59 (d, J = 10.9, 1H), 3.34 – 3.30 (m, 1H), 3.32 – 3.15
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(m, 2H), 3.12 – 3.17 (m, 1H), 2.82 -2.76 (m, 2H), 2.72 (dd, J = 12.4, 2.7, 1H), 2.68 (d, J
= 4.5, 1H), 2.63 – 2.57 (m, 1H), 2.51 – 2.46 (m, 1H).
13

C NMR (101 MHz, CDCl3) δ 208.17, 154.49, 137.61, 131.20, 122.57, 117.13, 108.32,

104.46, 99.87, 58.53, 55.26, 54.26, 52.14, 45.76, 41.59, 23.77.
Methyl

2-(8-methoxy-1,3,4,6,7,12b-hexahydroindolo[2,3-a]quinolizin-2(12H)-

ylidene)acetate (32; MA89): In a round-bottom flask, 350 mg of NaH in 60% of mineral
oil (8.76 mmol of NaH) was suspended in 20 mL of freshly dried THF and cooled to 0 °C
under argon atmosphere. Trimethylphosphonoacetate (1.27 mL; 8.76 mmol) was added
dropwise, forming a thick suspension that blocked magnetic stirring. This problem was
circumvented by addition of 40 mL of THF and the mixture was agitated for 30 minutes.
After this period, 8-methoxy-1,3,4,6,7,12b-hexahydroindolo[2,3-a]quinolizin-2(12H)-one
(31) (790 mg; 2.92 mmol) dissolved in THF was added and the reaction mixture was
stirred for 2 hours at room temperature. The excess of NaH was quenched with water and
the product was extracted with ethyl acetate, dried with Na2SO4, filtered and evaporated.
Isolation was carried out with flash chromatography employing a gradient of ethyl
acetate/hexanes to obtain 932 mg of a mixture of diastereomers (2.86 mmol; 98% yield).
MS [ESI] m/z 327.1 [M+ + H] for both diastereomers.
(Top spot on the TLC) 1H NMR (400 MHz, CDCl3) δ 8.00 (s, 1H), 7.03 (t, J = 8.0, 1H),
6.92 (d, J = 8.1, 1H), 6.47 (d, J = 7.8, 1H), 5.76 (s, 1H), 3.88 (s, 3H), 3.84 (d, J = 12.2,
1H), 3.73 (s, 3H), 3.35 (d, J = 11.2, 1H), 3.21 – 3.10 (m, 3H), 3.04 (dd, J = 16.1, 4.0,
1H), 2.65 – 2.59 (m, 2H), 2.50 – 2.44 (m, 3H).
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(Top spot on the TLC)

13

C NMR (101 MHz, CDCl3) δ 166.79, 154.52, 137.51, 131.25,

122.44, 117.30, 114.97, 108.36, 104.35, 99.87, 60.09, 55.26, 55.02, 52.47, 51.08, 40.58,
29.71, 29.18, 23.41.
Methyl

2-(8-methoxy-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-2-

yl)acetate (33; MA91): In a flask designed for hydrogenation was put 100 mL of
methanol, 90 mg of palladium on carbon (10%) and then 882 mg (2.7 mmol) of methyl 2(8-methoxy-1,3,4,6,7,12b-hexahydroindolo[2,3-a]quinolizin-2(12H)-ylidene)acetate (32)
dissolved in methanol. The mixture was agitated for 5 hours under hydrogen at 40 psi,
filtered under reduced pressure using Celite to remove the catalyst and the solvent
evaporated. Isolation was carried out by flash chromatography using a gradient of ethyl
acetate/hexanes. Yield 55% (490 mg; 1.49 mmol). MS (ESI) m/z 329.1 [M+ + H]. HPLC
purity 93%.
1

H NMR (400 MHz, CDCl3) δ 7.92 (s, 1H), 7.01 (t, J = 7.9, 1H), 6.89 (d, J = 8.0, 1H),

6.47 (d, J = 7.7, 1H), 3.88 (s, 3H), 3.73 (s, 3H), 3.20 (d, J = 11.3, 1H), 3.18 – 3.11 (m,
1H), 3.05 (d, J = 6.5, 1H), 3.00 (dd, J = 15.9, 4.8, 2H), 2.58 (td, J = 11.5, 4.6, 1H), 2.44 –
2.36 (m, 1H), 2.32 (dd, J = 13.4, 7.0, 2H), 2.26 (d, J = 7.5, 1H), 2.14 (d, J = 12.3, 1H),
1.78 (d, J = 11.6, 1H), 1.52 (qd, J = 12.3, 4.2, 1H), 1.34 – 1.25 (m, 1H).
13

C NMR (101 MHz, CDCl3) δ 173.14 (C19), 154.52 (C9), 137.40 (C13), 132.71 (C2),

122.02 (C11), 117.55 (C7), 108.03 (C8), 104.27 (C12), 99.81 (C10), 59.54 (C3), 55.33
(9-OCH3), 55.26 (C17), 53.44 (C5), 51.61 (19-OCH3), 40.98 (C18), 36.13 (C14), 33.04
(C15), 32.04 (C16), 23.76 (C6).
Methyl

2-(8-methoxy-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-2-

yl)acetate oxalate (MA91 OXA): In a 20 mL vial were added a solution of 51.0 mg
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(0.155

mmol)

of

methyl

2-(8-methoxy-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-

a]quinolizin-2-yl)acetate dissolved in diethyl ether and a solution of 114 mg (1.27 mmol)
of oxalic acid in ether. After addition of the oxalic acid solution, precipitation followed
immediately and the mixture was stirred for 30 minutes. The salt was filtered off under
reduced pressure and rinsed with ether to remove the excess of oxalic acid. It was
obtained 45.6 mg (0.109 mmol; 70% yield) of a white solid.
1

H NMR (400 MHz, DMSO) δ 11.06 (s, 1H), 6.97 (t, J = 7.8, 1H), 6.91 (d, J = 8.0, 1H),

6.46 (d, J = 7.5, 1H), 4.34 (br-s, 1H), 3.80 (s, 3H), 3.64 (s, 3H), 3.50 (br-s, 1H), 3.41 (d, J
= 10.9, 1H), 3.16 – 3.04 (m, 4H), 2.49 (s, 3H), 2.37 (ddd, J = 34.7, 15.7, 7.0, 2H), 2.17
(br-s, 1H), 1.86 (d, J = 13.7, 1H), 1.54 (dd, J = 23.4, 10.6, 1H), 1.41 (dd, J = 24.6, 11.8,
1H).
8-methoxy-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizine (34; MA104): To a
10 mL round-bottom flask equipped with a condenser with 4 mL of ethylene glycol, 100
mg (0.34 mmol) of 8-methoxy-1,3,4,6,7,12b-hexahydroindolo[2,3-a]quinolizin-2(12H)one (31) was dissolved along with 190 mg (3.4 mmol) of crushed KOH and 0.13 mL (2.7
mmol ) of hydrazine hydrate. The mixture was stirred at 190 °C for one hour before the
condenser was removed and then stirred for two hours. A solution of ammonium chloride
was poured into the flask and the crude extract obtained by extracting with three portions
of 30 mL of ethyl acetate, washing with brine. The solution was dried over anhydrous
sodium sulfate, filtered and evaporated. After purification with flash chromatography
(methanol/dichloromethane), it was obtained 78 mg (0.30 mmol; 84%) of solid. MS (ESI)
m/z 279.3 [M + Na+]. HPLC purity 94%.
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1

H NMR (400 MHz, CDCl3) δ 7.75 (s, 1H), 7.02 (t, J = 7.9, 1H), 6.91 (d, J = 8.1, 1H),

6.48 (d, J = 7.7, 1H), 3.89 (s, 3H), 3.21 (d, J = 11.4, 1H), 3.20 – 3.14 (m, 1H), 3.05 – 2.98
(m, 2H), 2.61 (td, J = 11.5, 4.5, 1H), 2.37 (td, J = 11.2, 3.5, 1H), 2.02 (d, J = 16.8, 2H),
1.89 (d, J = 12.2, 1H), 1.77 – 1.73 (m, 2H), 1.59 (ddd, J = 15.2, 12.5, 3.2, 1H), 1.52 –
1.44 (m, 1H).
13

C NMR (101 MHz, CDCl3) δ 154.50, 137.32, 133.14, 121.93, 117.61, 107.92, 104.22,

99.80, 60.24, 55.33, 53.86, 30.04, 29.96, 25.67, 24.28, 23.56.
8-methoxy-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizine

hydrochloride

(MA104 HCL): 8-methoxy-1,3,4,6,7,12b-hexahydroindolo[2,3-a]quinolizin-2(12H)-one
was dissolved in diethyl ether before a solution of HCl in ether was added and stirred for
approximately 30 minutes. A pale yellow solid (23 mg) was obtained after filtering,
washing with ether and dried under high vacuum.
1

H NMR (400 MHz, DMSO) δ 11.17 (s, 1H), 10.77 (s, 1H), 6.99 (t, J = 7.9, 1H), 6.93 (d,

J = 7.9, 1H), 6.47 (d, J = 7.5, 1H), 4.55 (t, J = 11.1, 1H), 3.81 (s, 3H), 3.56 (d, J = 6.4,
1H), 3.46 (d, J = 11.4, 1H), 3.34 (d, J = 13.7, 3H), 3.17 (dd, J = 23.1, 10.8, 1H), 3.06 (d,
J = 11.7, 1H), 2.57 (d, J = 13.0, 1H), 1.99 (dd, J = 26.1, 13.2, 1H), 1.91 – 1.82 (m, 1H),
1.73 (dd, J = 26.8, 13.6, 1H), 1.62 (dd, J = 24.8, 13.0, 1H).
Methyl

2-(8-methoxy-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-2-yl)-3-

oxopropanoate (35; MA106): To an oven-dried three-neck round-bottom flask equipped
with a thermometer was added 40 mL of anhydrous THF was dissolved 0.9 g (2.7 mmol)
of methyl 2-(8-methoxy-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-2-yl)acetate
(33). The solution was brought to -78 °C with a bath of dry ice in acetone while stirring
under argon. A solution of lithium diisopropylamide (3.4 mL; 6.8 mmol; 2M in THF)
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was added dropwise over 10 minutes while it was observed that the internal temperature
did not rise above -65 °C. The mixture was stirred for 30 minutes before the addition of
0.85 mL (13 mmol) of methyl formate and agitation for 3.5 hours at room temperature. A
solution of ammonium chloride was poured into the flask and the material was extracted
with three portions (30 mL) of ethyl acetate. The solvent was then evaporated and the
product purified using silica gel and a gradient of methanol/dichloromethane. After two
purifications by chromatography, the solid obtained weighed 93 mg (0.26 mmol; 9.6%).
MS (ESI) m/z 357.3 [M + 1].
1

H NMR (400 MHz, DMSO) δ 10.58 (s, 1H), 7.65 (s, 1H), 6.85 (dt, J = 15.2, 7.5, 2H),

6.39 (d, J = 7.4, 1H), 3.78 (s, 3H), 3.56 (s, 3H), 3.53 (s, 1H), 3.22 (s, 1H), 3.12 (d, J =
11.0, 1H), 2.93 - 2.88 (m, 2H), 2.82 – 2.78 (m, 2H), 2.44 – 2.38 (m, 1H), 2.33 – 2.28 (m,
1H), 2.19 - 2.09 (m, 1H) , 2.03 – 1.98 (m, 1H), 1.95 (t, J = 12.2, 1H), 1.39 (d, J = 12.5,
1H).
Methyl

3,3-dimethoxy-2-(8-methoxy-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-

a]quinolizin-2-yl)propanoate (36; MA107): To a round-bottom flask with a condenser
was dissolved 93 mg (0.26 mmol) of methyl 2-(8-methoxy-1,2,3,4,6,7,12,12boctahydroindolo[2,3-a]quinolizin-2-yl)-3-oxopropanoate (35) in 25 mL of methanol
along with 148 mg (0.78 mmol) of p-toluenesulfonic acid monohydrate and 0.28 mL (2.6
mmol) of trimethyl orthoformate. The mixture was stirred at reflux temperature under
argon for 2.5 hours and the solvent was evaporated under reduced pressure. Extraction
with ethyl acetate and aqueous sodium carbonate and purification with silica gel column
(3% methanol/dichloromethane) afforded 73 mg (0.18 mmol; 69% yield) of material. MS
(ESI) m/z 403.2 [M + 1].
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1

H NMR (400 MHz, CDCl3) δ 7.96 (d, J = 7.2, 1H), 7.01 (t, J = 7.9, 1H), 6.90 (d, J = 8.1,

1H), 6.46 (d, J = 7.8, 1H), 4.75 (dd, J = 16.5, 8.5, 1H), 3.87 (s, 3H), 3.67 (d, J = 10.4,
3H), 3.41 (s, 3H), 3.38 (d, J = 8.2, 3H), 3.21 (d, J = 11.0, 1H), 3.16 – 3.11 (m, 1H), 3.04
– 2.97 (m, 3H), 2.78 (dd, J = 8.5, 5.3, 1H), 2.55 (td, J = 11.4, 4.5, 1H), 2.43 - 2.34 (m,
1H), 2.17 (d, J = 12.8, 1H), 1.83 (d, J = 13.8, 1H), 1.72 – 1.63 (m, 1H), 1.57 – 1.52 (m,
1H), 1.43 - 1.37 (m, 1H).
13

C NMR (101 MHz, CDCl3) δ 171.86, 154.47, 137.42, 132.67, 121.97, 117.48, 107.82,

104.35, 99.73, 60.42, 55.28, 55.27, 55.19, 52.88, 51.63, 35.49, 34.61, 32.52, 30.54, 28.24,
23.68, 21.03.
(E)-methyl

3-methoxy-2-(8-methoxy-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-

a]quinolizin-2-yl)acrylate

(37;

MA108):

In

approximately

1

mL

of

N,N-

dimethylformamide was dissolved 70.8 mg (0.178 mmol) of methyl 3,3-dimethoxy-2-(8methoxy-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-2-yl)propanoate (36) and a
total of 74 mg (0.6 mmol) of potassium tert-butoxide. The reaction was maintained under
agitation at approximately 60 °C for 6 hours before aqueous solution of ammonium
chloride was added. The mixture was extracted with three portions of ethyl acetate and
washed twice with brine. After drying with sodium sulfate, filtering and purifying twice
by chromatography, it was obtained 20.1 mg (0.054 mmol) with a 31% yield. MS (ESI)
m/z 371.2 [M + 1].
1

H NMR (400 MHz, CDCl3) δ 8.21 (s, 1H), 7.32 (s, 1H), 6.99 (t, J = 7.8, 1H), 6.87 (d, J

= 8.1, 1H), 6.44 (d, J = 7.6, 1H), 3.84 (s, 3H), 3.75 (s, 3H), 3.70 (s, 3H), 3.25 (d, J = 11.6,
1H), 3.11 (d, J = 11.5, 2H), 3.00 (d, J = 17.4, 1H), 2.87 (t, J = 11.8, 1H), 2.61 - 2.55 (m,
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1H), 2.42 (t, J = 11.8, 1H), 2.34 - 2.25 (m, 1H), 2.14 (dd, J = 23.8, 11.8, 1H), 1.92 (d, J =
13.4, 1H), 1.61 - 1.56 (m, 2H).
13

C NMR (101 MHz, CDCl3) δ 169.16, 159.99, 154.47, 137.52, 132.64, 121.90, 117.48,

112.94, 107.50, 104.40, 99.65, 61.59, 60.13, 55.67, 55.23, 51.31, 33.68, 33.92, 29.69,
23.35, 22.68.
(E)-methyl

3-methoxy-2-(8-methoxy-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-

a]quinolizin-2-yl)acrylate hydrochloride: A few milligrams of (E)-methyl 3-methoxy2-(8-methoxy-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-2-yl)acrylate (37) was
dissolved in THF before a solution of hydrochloric acid in diethyl ether was added
dropwise. The suspension formed was stirred and then the solvents evaporated under
reduced pressure to afford an yellowish solid.
1

H NMR (500 MHz, DMSO) δ 11.17 (s, 1H), 10.57 (s, 1H), 7.50 (s, 1H), 7.01 (t, J = 7.8,

1H), 6.93 (d, J = 8.1, 1H), 6.50 (d, J = 7.6, 1H), 4.71 (t, J = 8.0, 1H), 3.88 (s, 3H), 3.84
(s, 3H), 3.65 (s, 3H), 3.63 (s, 1H), 3.53 (d, J = 11.1, 1H), 3.36 - 3.27 (m, 3H), 3.12 - 3.10
(m, 2H), 2.47 (d, J = 11.6, 2H), 2.30 (dd, J = 25.2, 12.4, 1H), 1.71 (d, J = 12.6, 1H).
methyl

2-((7a)-7a-hydroxy-8-methoxy-1,2,3,4,6,7,7a,12b-octahydroindolo[2,3-

a]quinolizin-2-yl)acetate (38; MA116): To a mixture of 2.5 mL of acetonitrile and
0.8mL of water was added 61.0 mg (0.186 mmol) of methyl 2-(8-methoxy1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-2-yl)acetate (33). The solution was
brought to 0 °C and stirred under argon before a solution of 79.9 mg (0.186 mmol) of
[bis(trifluoroacetoxy)iodo]benzene (PIFA) in 0.75 mL of acetonitrile was added dropwise
over a period of five minutes. After stirring for two hours, the mixture was poured into an
aqueous solution of K2CO3 (pH=9), extracted with three portions of 25 mL of ethyl
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acetate, washed with brine, dried with anhydrous sodium sulfate, filtered and evaporated
under reduced pressure. The product was purified by preparative HPLC, giving 9.8 mg
(0.028 mmol; 15% yield) of an orange solid. HPLC analysis showed 94.3% purity. MS
(ESI) m/z 345.04 [M + H]+.
1

H NMR (400 MHz, CDCl3) δ 7.31 (t, J = 8.0, 1H), 7.20 (d, J = 7.6, 1H), 6.75 (d, J = 8.2,

1H), 3.87 (s, 3H), 3.68 (s, 3H), 3.16 (dd, J = 11.0, 2.3, 1H), 3.00 (dt, J = 11.2, 3.0, 1H),
2.83 (td, J = 12.2, 2.6, 1H), 2.72 – 2.70 (m, 1H), 2.68 (s, 1H), 2.64 (t, J = 2.2, 1H), 2.45 –
2.37 (m, 2H), 2.27 (dd, J = 15.6, 7.6, 1H), 2.15 (dd, J = 13.1, 2.9, 1H), 2.05 – 1.95 (m,
1H), 1.78 (d, J = 12.6, 1H), 1.68 – 1.59 (m, 2H), 1.37 (td, J = 12.6, 3.8, 1H).
13

C NMR (101 MHz, CDCl3) δ 183.52, 173.02, 155.91, 154.68, 131.03, 126.31, 114.23,

109.10, 80.88, 59.43, 55.46, 55.38, 51.54, 49.74, 40.96, 35.91, 32.93, 32.39, 29.71.
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12. General bioassay procedure
12.1.

Materials

All chemicals used were from Sigma-Aldrich (Poole, Dorset, U.K.) with the
following exceptions. For the binding experiments, [3H]DAMGO (53.4 Ci/mmol), [3H]U69,593 (42.7 Ci/mmol), [3H]Enkephlin (45 Ci/mmol), were obtained from Perkin-Elmer
Life Sciences Inc. (Boston, MA, U.S.A.). DAMGO, DPDPE, nor-Binaltorphimine were
obtained from Tocris Bioscience (Ellisville, Missouri, U.S.A.).
12.2.

Cell culture

CHO-K1 cells stably transfected with opioid receptor subtypes µ, δ, and κ were a
generous gift from Roth labs. (University of North Carolina at Chapel Hill, Chapel Hill,
N.C., U.S.A.). These cells were maintained at 37oC and 5% CO2 in a DMEM nutrient
mixture supplemented with 2 mM L-glutamine, 10% fetal bovine serum, 0.5% penicillin–
streptomycin, and either G418 (600 mg/mL) or hygromycin B (300 mg/mL).
Membranes were prepared by scraping the cells in a 50mM Tris buffer, homogenized via
sonication and centrifuged for 40 minutes at 13650 rpm at 4oC. These were kept at -80oC.
Protein concentration was found via Bio-Rad Protein Assay (Hercules, California,
U.S.A), an adaptation of the Bradford method of protein determination100.
12.3.

Radio-ligand binding for opioid receptor subtypes

Opioid binding took place under the following conditions: 10μM of each
compound was incubated with [3H]DAMGO (µ), [3H]U-69,593 (κ),or [3H]Enkephlin (δ)
for 60 minutes in a 96-well plate . Tritium and membrane concentration for each cell line
is determined by saturation experiments performed after each batch of membrane is
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scraped.

The reaction was terminated via rapid vacuum filtration through GF/B filters

presoaked with 0.3% BSA using a Perkin Elmer 96-well Unifilter followed by 10 washes
of 50 mM Tris. Plates were read using a Perkin Elmer Topcount. Total binding was
defined as binding in the presence of 0.1% DMSO. Non-specific binding was defined as
binding observed in the presence of 10μM DAMGO (µ), nor-Binaltorphimine (κ),or
DPDPE (δ). Specific binding was the difference between total and non-specific binding.
Percent binding was found with the following formula:
100-(Binding of compound- non-specific binding)*100/Specific Binding
To obtain a dose response curve, concentrations of compound ranging from
100µM to 48nM were incubated for 60 minutes in a 96-well plate with a predetermined
amount of [3H] specific to each membrane type. Optimal membrane concentration was
also predetermine by a saturation experiment. The reaction was terminated via rapid
vacuum filtration through GF/B filters presoaked in 0.3% BSA using a Perkin Elmer 96well Unifilter followed by 10 washes of 50mM Tris. Plates were read using a Perkin
Elmer Topcount . Total binding was defined as binding in the presence of 0.1% DMSO.
Non-specific binding was defined as binding observed in the presence of 10 μM of the
control specific for the receptor of interest. Specific binding was the difference between
total and non-specific binding. Ki and IC50 values were calculated using the software
Graph-Pad Prism 5.
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